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Preface 
Chronic hyperglycaemia observed in diabetic patients has been associated with the 
development of cardiovascular complications, which increases the risk of heart failure. In 
addition, hyperglycaemia induces haematological changes that compromise red blood cell 
function thus decreasing the oxygen-carrying capacity of the blood to the cardiovascular 
system, further aggravating cardiac disorders. The use of anti-diabetic agents have been 
associated with the progression of the pathology of haematological and cardiac function 
disorders. The World Health Organization however, has proposed the use of medicinal plants 
as an alternative as some of these plants possess anti-hyperglycaemic and cardio-protective 
properties which is of benefit in alleviating hyperglycaemia-induced cardiovascular 
complications. The goal therefore, is to investigate the effects of Momordica balsamina 
methanolic extract on haematological and cardiovascular function which may bring to light, 
the mechanisms by which this plant may use to ameliorate hyperglycaemia-induced 
cardiovascular complications in a streptozotocin-induced diabetic rat model. 
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Study outline 
The current dissertation is presented in manuscript format. It consists of 7 sections viz. 
dissertation abstract, chapter 1: introduction/literature review, chapter 2: manuscript 1, chapter 
3: manuscript 2, chapter 4: synthesis, conclusions, and appendices. The dissertation abstract 
states the purpose of the study and summarizes the findings of the study. Chapter 1 is a brief 
background and a germane literature review to highlight the gaps that exist in literature and 
how the current study aims to fill these gaps. Chapter 2 is the first novel research paper that 
seeks to evaluate the effects of a medicinal plant, Momordica balsamina methanolic extract on 
cardiovascular dysfunction. A.Ludidi, A Khathi, N.H Sibiya and P.S Ngubane are authors to 
this paper. The manuscript is currently under review in the journal of Chemico-Biological 
Interaction. Chapter 3 entails the second research study manuscript, which sought to investigate 
the effects of Momordica balsamina methanolic extract on haematological function, which 
may unveil some of the mechanisms by which this plant may exert its cardio-protective effects. 
A Ludidi, M.C Baloyi, A Khathi, N.H Sibiya and P.S Ngubane are authors to this paper. The 
manuscript is prepared for submission to the journal of Biomedicine and pharmacotherapy. 
Chapter 4 is the synthesis, which discusses the link between the two studies and highlights the 
main findings for the specific aims of the current project. Appendices include the letter of 
ethical clearance, abstract and certificate of presentations to various conferences and journal’s 
guideline to authors for both research papers. 
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Abstract 
Background 
The hyperglycaemia-induced haemanetic changes reduces the oxygen-carrying capacity of 
erythrocytes, thus aggravating cardiovascular disorders in diabetic patients. The conventional 
therapies have been shown to be associated with the progression of haematological and 
cardiovascular dysfunction, which may not be favorable for patients with congestive heart 
failure. We have previously shown the anti-hyperglycaemic and antioxidant properties of 
Momordica balsamina (MB) methanolic extract which may be of benefit in alleviating 
cardiovascular disorders, thus providing an effective alternative therapy. The current study 
therefore, investigated the short-term effects of MB methanolic extract on cardiovascular and 
haematological function in streptozotocin-induced diabetic rats.  
Methods 
Briefly, air-dried MB leaves were extracted with methanol to yield a methanolic extract. STZ-
induced diabetic rats were divided into untreated and treated groups with insulin (170 μg kg-1 
s.c.) and metformin (500 mg kg-1 p.o.) as standard drugs. MB (250 mg kg-1 p.o.) was 
administered twice daily for 5 weeks. Blood glucose concentration, body weight and blood 
pressure were monitored weekly for 5 weeks. Terminally, animals were sacrificed after which 
blood, heart and kidneys were collected for haematological and biochemical analysis. 
Histological analysis was also performed on the hearts.  
Results 
MB significantly decreased blood glucose concentration from week 3-5 by comparison with 
diabetic untreated animals. Treatment with MB reduced oxidative stress in the plasma, kidney 
and heart while improving their antioxidant status compared with untreated diabetic animals. 
This was associated with increased EPO secretion by the kidneys thus improving RBC 
production and haemoglobin concentrations. MB moderately increased erythrocyte indices: 
mean cell volume (MCV), mean cell haemoglobin concentration (MCHC) and mean 
corpuscular haemoglobin (MCH) by comparison with untreated diabetic animals. MB 
ameliorated heart hypertrophy and decreased CRP, CT-I and Ang-II concentrations by 
comparison with untreated diabetic animals. MB also decreased MAP by comparison with 
untreated diabetic animals.  
xxi 
 
Conclusion 
MB administration protects against hyperglycaemia-induced cardiovascular and 
haematological changes by attenuating hyperglycaemia, oxidative stress in both the kidney and 
heart tissues of STZ-induced diabetic rats, which may reduce the risks of cardiac myopathology 
complications in diabetes mellitus.
1 
 
Chapter 1: Literature review 
1. Background  
Sustained hyperglycaemia is the pathogenic feature of DM which has been shown to result in 
microvascular and macrovascular complications (1, 2). Macrovascular complications have 
been found to be the most common cause of deaths amongst diabetic patients with 
cardiovascular disorders accounting for 52% of deaths in type 2 diabetes mellitus (T2DM) and 
44% in type 1 diabetes mellitus (T1DM) (3, 4). Studies indicate that hyperglycaemia-induced 
haematological changes such as altered red blood cell function play a significant role in the 
progression of cardiac dysfunction (5). Although conventional treatment decreases 
hyperglycaemia, their use is associated with undesirable side effects which amongst many 
include increased blood viscosity which is of concern in patients with congestive heart failure 
(6). As a result, the progression of macrovascular complications intensifies even during 
treatment (7, 8). There is therefore, a need for alternative treatment, which will lower blood 
glucose concentration and alleviate complications associated with diabetes. Medicinal plants 
have been shown to possess, with minimal side effects, anti-hyperglycaemic and cardio-
protective effects in STZ-induced diabetic animal models and therefore could potentially serve 
as an effective alternative (9-11). The mechanisms by which these medicinal plants exert their 
hypoglycaemic, anti-hyperglycaemic effects and ameliorate hyperglycaemia-induced 
cardiovascular disorders, are still to be fully understood. We have previously reported on the 
anti-hyperglycaemic and reno-protective properties of Mormodica balsamina, which may be 
beneficial in alleviating hyperglycaemia-induced cardiac dysfunction. This study therefore, 
investigated whether Mormodica balsamina can avert the decline of cardiac function often seen 
in diabetic humans and animal models. The following section discusses the effects of 
hyperglycaemia on cardiac function.  
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1.1 Effects of hyperglycaemia on cardiovascular function  
Hyperglycaemia has been shown to increase reactive oxygen species (ROS) including 
superoxide resulting in oxidative stress, which induces mitochondrial dysfunction through 
caspase 3 activation, which induces apoptosis in cardiomyocyte (12, 13). Furthermore, ROS 
activates scramblases in red blood cell (RBC) membrane to expose phosphatidylserine (PS) to 
the extracellular space, where annexin-V, a marker for RBC undergoing apoptosis, which 
targets it for engulfment by macrophages (14, 15). The latter decreases RBC count which 
decreases the oxygen carrying capacity of blood, further aggravating cardiac dysfunction due 
to decreased oxygen supply to the cardiomyocytes. Studies however, have shown that some 
medicinal plants have the ability to decrease caspase 3 activation which may delay apoptosis 
in cardiomyocyte (16).  
Other mechanisms that induce cardiac cell death include the increased activation of the polyol 
and protein kinase C (PKC) pathways and advanced glycation end products (AGEs) formation 
which are further discussed below (17-21). 
1.1.1 The role of the polyol pathway in cardiac dysfunction  
The polyol pathway is a metabolic pathway where aldose reductase (AR) uses nicotinamide 
adenine dinucleotide phosphate (NADPH) as its cofactor to reduce excess glucose to sorbitol. 
In addition, NADPH is required as a cofactor during the catalytic regeneration of glutathione 
by glutathione reductase which is an antioxidant enzyme (22). The accumulation of sorbitol 
as seen in cardiac cells induces osmotic stress which has been proposed to promote apoptosis, 
however the mechanism is still unknown (23). Sorbitol is oxidized by sorbitol dehydrogenase 
to fructose with nicotinamide adenine dinucleotide (NAD+) being reduced to NADH (24). 
Hyperglycaemia therefore decreases the NAD+/NADH ratio (25). However medicinal plants 
have been shown to possess phytochemicals that inhibit AR which may protect the heart from 
ischemic injury (26, 27). Furthermore, the up regulation of the polyol pathway has been shown 
to promote ROS production thus activating other cellular damaging mechanisms such as the 
protein kinase C (PKC) pathway which has been shown to induce haematological changes 
that shorten the life span of erythrocytes , further promoting cardiovascular dysfunction (28).  
1.1.2 The role of the protein kinase C (PKC) pathway in cardiac dysfunction 
As mentioned previously, the up regulation of the polyol pathway decreases the 
NAD+/NADH ratio, which blocks NAD+-dependant glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) from converting glyceraldehyde 3-phosphate (G3P) to 1,3 
bisphosphoglycerate (1,3 BPG) (29). As a result, there is an increased amount of G3P, which 
3 
 
is a substrate for the synthesis of α-glycerol phosphate (29, 30). Furthermore, α-glycerol 
phosphate is a precursor of diacylglycerol (DAG) and DAG is known to activate some protein 
kinase C (PKC) isoforms (31). In the hearts of diabetic patients, both PKC-α and PKC-β 
isoforms are both upregulated which is associated with an irregular contractility progressing 
towards heart failure (32). The activation of the PKC has also been linked with the decreased 
RBC deformability thus inducing eryptosis (33). Medicinal plants such as Centaurium 
erythraea however, have been shown to decrease the activation of PKC in erythrocytes 
thereby restoring RBC membrane integrity and reducing the rate of agglutination (34, 35). 
1.1.3 The role of advanced glycation end products (AGEs) in cardiac dysfunction 
Hyperglycaemia has been shown to be associated with increased advanced glycation end 
products (AGEs) (36). AGEs develop when a reducing sugar such as glucose reacts non-
enzymatically with an amino group of a protein to form Amadori products (37, 38). Then after 
days to weeks, the Amadori products undergo reactions that further rearrange to form 
irreversibly cross-linked senescent macroprotein derivatives which are called AGEs (37). 
When an AGE interacts with its receptor (RAGE), it generates oxidative stress in various cell 
types including cardiomyocytes and evoke inflammatory and thrombogenic reactions (39). 
AGEs thus play a significant role in the development and progression of cardiovascular 
complications in diabetic patients thus their formation and accumulation progress at accelerated 
rates in diabetic patients (40). Furthermore, AGEs have also been shown to induce the cross-
linking of integral membrane proteins such as the sodium-potassium pump (Na +/K + ATPase) 
of erythrocytes, resulting in the reduced activity of this pump (41, 42). Medicinal plants 
however, have been shown to possess flavonoids which decrease the AGEs-induced ROS 
production, this way restoring the function of glycated enzymes (43). The increased formation 
of AGEs, enhanced production of reactive oxygen species (ROS) and stimulation of protein 
kinase C (PKC), have been proposed to contribute to the endothelial dysfunction in diabetic 
patients which is further discussed below (44, 45).  
1.2. Endothelial dysfunction 
Free radicals also target and modify major extra-cellular and long lived proteins such as elastin, 
laminin and collagen to form glycoproteins (46). The presence of these glycoproteins in the 
vascular wall is associated with the development of endothelial dysfunction and cardiovascular 
complications including atherosclerosis (47). In addition, hyperglycaemia contributes to the 
progression of cardiovascular dysfunction, however, dislipidaemia, is another factor that 
contributes to endothelial dysfunction resulting in the development of cardiac dysfunction (48). 
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Endothelial dysfunction is defined as the inability of the endothelium to maintain vascular 
homeostasis, which is also associated with the decreased bioavailability of nitric oxide (NO) 
(49). This decrease is caused by the decreased expression of endothelial cell NO synthase 
(eNOS), inefficient eNOS activation, insufficient substrate or cofactors for eNOS and lastly, 
the accelerated degradation of NO2 by ROS (50, 51). As a result, endothelial dysfunction is 
accompanied by increased vasoconstrictors including endothelin-1 (ET-1) and angiotensin 
II (49, 52). Additionally, there is increased thrombosis, cell growth in the vascular walls and 
poor regulation of inflammation (52). The endothelium orchestrates the production of 
vasodilators including NO, prostacyclin, and endothelium-derived hyperpolarizing factor 
(EDHF) in order to maintain arterial tone and blood flow (53). Both vasoconstrictors and 
vasodilators work in synergy to maintain a homeostatic arterial patency and compliance (52). 
The pathology of endothelial dysfunction therefore results in increased arterial tone, which 
promotes vasospasm and increased arterial stiffness (54). Shear stress is the frictional force 
between blood flow and the endothelial wall (55). An increase in blood flow, increases shear 
stress however the diameter of the vessel is inversely proportional to shear stress (56). In 
healthy arteries, an increase in arterial flow which alters the diameter stimulates a “flow-
mediated dilation”, therefore decreasing shear stress, thus maintaining homeostasis (57). 
Additionally, the endothelium plays a role in maintaining the chronic changes in the structure 
of the arterial lumen because of chronic changes in blood flow (58). Endothelial dysfunction 
therefore contributes to the clinical expression of atherosclerosis leading to cardiovascular 
dysfunction (59). Atherosclerosis is the narrowing of the arteries due to endothelial injury 
and inflammation (60). Additionally, the accumulation of the oxidized low-density 
lipoprotein (LDL) particles in the arterial walls may be promoted by a vasoconstrictor known 
as angiotensin II (Ang- II),resulting in vascular blockage (61). The inhibition of vascular blood 
flow eventually leads to the bursting of the vascular wall (62). Furthermore, oxidized LDL 
accumulation, results in monocyctes infiltrating the arterial wall and differentiate into 
macrophages in order to accumulate oxidized lipids to form foam cells (63). These foam cells 
stimulate macrophages proliferation and attract T-lymphocytes. T-lymphocytes induce 
smooth muscle proliferation in the arterial walls and collagen accumulation resulting in the 
formation of a lipid-rich atherosclerotic lesion with a fibrous cap. Vascular occlusion is 
increased thereby increasing the risk of rupture, which further contributes to cardiovascular 
dysfunction. ROS has also been shown to also induce the nuclear factor-kappa B (NF-κB) to 
transcriptional activation of many transcriptional genes relevant to inflammation, immunity 
and atherosclerosis (64). As a result, there is elevated tumour necrosis factor α (TNF α), plasma 
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cardiotropin-I and C-reactive protein concentration in the circulation (65). These pro-
inflammatory cytokines serve as experimental markers for the progression of cardiovascular 
diseases (65).  
In addition, hyperglycaemia increases the accumulation of sorbitol in the cells, thus, osmotic 
stress has been postulated to underly the mechanism involved in the development of diabetic 
microvascular complications (66). Medicinal plants such as Portulca oleracea L. have been 
shown to improve endothelial dysfunction by promoting the activity of eNOS thereby restoring 
vasodilation and vasoconstriction which may improve the increased blood pressure of diabetic 
patients which may further improve cardiac dysfunction (67, 68).  
Hyperglycaemia has also been shown to induce haemanetic changes including RBC 
dysfunction associated with an increased risk of developing cardiac dysfunction and diabetic 
anaemia if left untreated. These haemanetic changes are further discussed below. 
1.3. Effects of hyperglycaemia on red blood cell function 
1.3.1 Effects of hyperglycaemia-induced ROS on red blood cell function 
Amongst the several factors that contribute to the haematological changes in diabetic patients, 
hyperglycaemia increases free radical accumulation resulting in oxidative stress, which target 
and damage cellular molecules namely: protein and lipids eventually altering cellular function 
(69-71). The up regulation of the polyol pathway as mentioned in the above section, increases 
the accumulation of sorbitol which results in osmotic stress (72). Osmotic stress has been 
shown to induce red blood cell (RBC) shrinkage as observed by a decrease in mean corpuscular 
volume (MCV) in diabetic patients (73, 74). The shrinkage of RBCs disturbs membrane 
proteins such calcium (Ca2+) channels resulting in RBC death, a process known as eryptosis 
(75). Activated Ca2+channels increase intracellular influx of Ca2+, which activate 
aminophospholipid translocases (APLT) that activate phospholipid scramblases (PLSCR) thus 
inducing the exposure of phosphatidilne serine (PS) to the extracellular fluid (76). In addition, 
conversion of sorbitol to fructose, which is further metabolized to fructose-3-phosphate by 3-
phosphokinase (3-PK), results in the generation of 3-deoxyglucosone (3-DG ) (77).  3-DG is 
the central precursor of an array of AGEs, particularly carboxymethyllysine (CML)–protein 
adducts in erythrocytes (78). CML adducts have been shown to increase to thiobarbituric acid 
reactive substances (TBARs) including malondialdehyde (MDA) which increases oxidative 
stress thus increasing RBC membrane rigidity, decreasing the life-span of RBCs and promoting 
eryptosis (79). Cardiovascular function is therefore compromised; however, there are 
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scavenging systems or antioxidants such as superoxide dismutase (SOD), which neutralizes 
ROS. Furthermore, the imbalance of these protective antioxidant mechanisms due to 
hyperglycaemia as seen in DM, is associated with other complications such as increased lipid 
peroxidation (80). Medicinal plants such as Ferulga angulata have been shown to contain 
bioactive compounds that improve the antioxidant status including decreasing lipid 
peroxidation levels of experimental diabetic animals (81, 82). This could be of benefit in red 
blood cell function since lipid peroxidation induces hemolysis of RBC, thus increasing the risk 
of cardiovascular complications (83). 
1.3.2 Effects of lipid peroxidation on RBC function 
Lipid peroxidation is a result of increased ROS, with the hydroxyl radical (OH-) and 
hydroperoxyl (OH-2) profoundly affecting lipids. The OH- radical is the most chemically 
reactive species of the ROS and produced from O2 in cell metabolism. Lipid peroxidation is 
described as the process of oxidants such as free radicals or non-radical species attack lipids 
containing carbon-carbon double bond (s), that involve hydrogen abstraction from a carbon, 
with oxygen insertion resulting in lipid peroxyl radicals and hydroperoxides. Glycolipids, 
phospholipids and cholesterol and polyunsaturated fatty acids (PUFA) are targets for damaging 
and peroxidative modification (84). PUFA arachidonic acid, which is a component of cell 
membrane phospholipids, is peroxidized to finally form malondialdehyde (MDA) which is 
used as a biomarker for lipid peroxidation. The accumulation of MDA increases intracellular 
fluid viscosity, which disturbs haemoglobin (Hb) function, ultimately altering the function of 
RBC indices as observed by the decreased mean corpuscular volume (MCV), mean corpuscular 
haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC). As a result 
of prolonged decreased Hb concentrations, anaemia ensues due to the decreased Hb 
transporting oxygen to cells. The changes in RBC indices also result in decreased RBC fragility 
which is associated with a disrupting in the asymmetry of membrane phospholipids where cell 
membrane scrambling occurs accompanied with phosphatidylserine (PS) translocation to the 
external cell surface (85). PS exposure signals for eryptosis through phagocytosing cells 
engulfing targeted RBCs resulting in the rapid clearance of the affected erythrocytes (86). The 
increased rate of eryptosis, which invariably leads to the development of anaemia thus 
aggravating cardiovascular dysfunction (87, 88). However, the ability of some medicinal plants 
such as Nigella sativa, to stabilise the fragility of RBC thus decrease the rate of rupturing, 
which prolongs the life span of erythrocytes therefore, may improve diabetic myopathy (89, 
90). 
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1.4 Effects of hyperglycaemia on erythropoietin secretion 
Hyperglycaemia-induced microvascular complications including nephropathy, have been 
shown to be associated with a decrease in red blood cell formation since the kidney is the 
primary stimulus for erythropoiesis via erythropoietin (EPO) secretion (91, 92). Diabetic 
patients, as a result, develop anaemia if left untreated (93, 94). However, diabetic anaemia 
arises from a number of factors such as increased reactive oxygen (ROS) species and lipid 
peroxidation (95, 96). Some isolated derivatives of medicinal plants such as chlorigenic, 
caffeine and ferulic acid have been shown to improve EPO secretion thus erythropoiesis in 
experimental animals however (97, 98).  
It is clear therefore that treatment strategies, should aim to lower blood glucose and alleviate 
hyperglycaemic-induced micro and macrovascular complications (99). 
1.5. Management strategies 
The management of hyperglycaemia and DM associated complications relies on various 
treatment strategies, which involves the use of anti-hyperglycaemic agents such as biguanides, 
sulphonylureas, alpha glucosidase inhibitors, thiozolidinediones and insulin injections (100). 
Metformin and insulin however, have been shown to affect cardiac and RBC function as 
highlighted below. 
1.5.1 Metformin 
Biguanides such as metformin, decreases hepatic glucose output and decreases fasting 
glycaemia (101). However, it may lead to renal dysfunction as it may increase lactic acidosis 
which is extremely rare (less than 1 case per 100,000 treated patients) but potentially fatal 
(102). Although metformin has been shown to have cardio-protective effects, it has been shown 
to contribute to the progression of anaemia through the malabsorption of vitamin B12 which is 
important for erythropoiesis and RBC maturation (103).  
1.5.2 Insulin 
Insulin is currently the primary means of treatment for DM however, the administration of 
insulin as a bolus is associated with hyperinsulinaemia which increases blood volume thus 
inducing cardiac failure (104). Increased blood volume/ venous return over prolonged periods, 
induces cardiac hypertrophy (105). Insulin has also been shown to promote fibrosis in cardiac 
muscle which disturbs cardiac contractility. Furthermore, increased insulin has also been 
shown to increase sodium retention and hence increases plasma volume and ultimately blood 
pressure (106). An increase in plasma volume is of concern in patients with congestive heart 
failure (107). Insulin has been shown to promote RBC agglutination which increases blood 
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viscosity and mean arterial pressure (MAP) which further aggravates cardiac dysfunction 
(107).  
Studies have also indicated that conventional drugs are still not accessible in some parts of our 
rural communities (108-110). There is therefore a need for alternative treatment strategies that 
will lower blood glucose and alleviate hyperglycaemia-induced micro and macrovascular 
complications (111). Medicinal plants have been shown to possess, with minimal side effects, 
anti-hyperglycaemic, reno and cardio-protective effects in STZ-induced diabetic animal 
models and therefore could potentially serve as an effective alternative (112-116). The 
mechanisms by which these medicinal plants exert their hypoglycaemic, anti-hyperglycaemic 
and ameliorate hyperglycaemic induced complications such as cardiovascular disorders, are 
still to be fully understood. In this study, the focus is on Momordica Balsamina’s effect on 
selected markers for cardiovascular and haematological function. 
1.5.3 Medicinal plants and their effects on haematological and cardiovascular function 
Various medicinal plants such as Parkia biglobosa, Cyclopia maculata (honeybush) 
Momordica charantia, Syzygium cordatum (Hochst.) have been shown to possess anti-
hyperglycaemic, reno-protective, cardiovascular effects and haemoprotective activities (117-
120). These are amongst several thousands of medicinal plants used to manage diabetes in 
Africa (121, 122). Parkia biglobosa called by different local names such as ‘afitin’ in Benin 
City, Nigeria, has been shown to initiate insulin secretion from the pancreatic beta cells, 
however the seeds are often fermented and consumed for nutritional condiment (123). In 
addition, Parkia biglobosa has been shown to improve red blood cell count and haemoglobin 
concentrations of streptozotocin-induced diabetic rats (124). Cyclopia maculata (honeybush) 
which is rich in hesperidin has been shown to possess cardio-protective effects via the 
PPAR-c pathway in an ischemic heart disease model in diabetic rats (125). In addition, pre-
treatment with hesperidin was shown to significantly improve mean arterial pressure, reduce 
left ventricular end-diastolic pressure, and improve both inotropic and lusitropic function of 
the heart as compared to controls (125). A plant derived flavanol with antioxidant properties, 
epigallocatechin-gallate (EGCG), has been shown to protect ROS induced cellular DNA, 
with a much higher potency in reducing lipid peroxidation, as a result, RBC membrane 
integrity may be improved (108, 126, 127). Momordica charantia; Karela (Hindi) and Bitter 
Gourd (English) is a common folklore remedy for DM as it has demonstrated anti-
hyperglycaemic effects in various animal models (128). Extracts from the leaves, fruit pulp, 
seeds and the whole plant are used to treat diabetes in various anima models (128). Shibib and 
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colleagues, have previously shown an ethanolic extract of Momordica charantia to be anti-
hyperglycaemic and stimulate erythropoiesis in STZ-induced diabetic rats (129). Razif, et al. 
have also shown the cardio-protective effects of Momordica charantia through improving the 
disturbed metabolism of the vasodilator nitric oxide, thereby decreasing blood pressure (130). 
However, the study focused on the function of the aorta and vascular function and did not 
highlight the effects of Momordica charantia on the cardiac muscle. Furthermore, studies 
conducted on Momordica charantia have not fully explored the effects of this plant on RBC 
structure and function (131). In our laboratory, we have previously shown anti-hyperglycaemic 
effects of leaf extracts from Syzygium cordatum (Hochst.) [Myrtaceae] (132). This plant has 
been shown to possess bioactive compounds such as masilinic acid (MA) which possesses 
reno-protective and cardio-protective effects through a number of mechanisms including 
decreasing oxidative stress while improving the antioxidant status which may be of benefit in 
alleviating haematological changes induced by oxidative stress as a result of hyperglycaemia 
(133). However, the structure and markers for cardiac damage such as hypertrophy which is 
marked by an increase in cardiotropin-I, was not evaluated to further establish the cardio-
protective effects of MA in these animals. Furthermore, cardiac damage is further aggravated 
by RBC dysfunction which has also not been assessed in studies that use Syzygium 
cordatum (Hochst.) [Myrtaceae] as treatment. The effects of Syzygium cordatum on 
haematological parameters are therefore not fully understood.  
 Medicinal plants evidently improve cardiac function and erythropoiesis; however, further 
investigations are warranted on their effects on red blood cell structure and function. 
Compromising RBC structure increases the risk of RBC haemolysis and clearance, which 
exacerbates cardiac dysfunction in diabetic patients. Studying RBC function provides a tool to 
understand the mechanism/s by which these medicinal plants exert their cardio-protective 
effects. 
1.6 Basis of the study 
Of interest to our study is Momordica balsamina, a plant commonly known as “Intshungu” in 
isiZulu, South Africa, which is in the same family as Momordica charantia. Momordica 
balsamina is an African pumpkin that belongs to the cucurbitaceae family of plants widespread 
in Namibia, Botswana, Swaziland and all provinces of Southern Africa (134). The seeds, fruits, 
leaves and stems have been reported to contain nutritional and medicinal compounds that 
render them anti-hyperglycaemic (135). However, the effects of this plant on hyperglycaemic 
induced haematological changes and cardiovascular dysfunction have not been shown. In our 
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laboratory however, we have recently shown that MB possesses anti-hyperglycaemic and reno-
protective effects and ameliorates kidney dysfunction in STZ-induced diabetic rats (136). 
Against this background, we investigated the effects of MB on cardiac dysfunction since 
renoprotection has been shown to be associated with improved EPO secretion, erythropoiesis 
and cardiovascular dysfunction in diabetic animal models (136). In addition, since we have 
previously shown the anti-hyperglycaemic effects of MB in STZ-induced diabetic rats, we 
sought to also investigate the effects of MB on hyperglycaemic induced red blood cell 
dysfunction in STZ-induced diabetic rats. This is in an effort to establish the mechanisms by 
which MB may improve cardiac dysfunction.  
1.7 Aim 
The aim of the study therefore is to evaluate the effects of Momordica balsamina methanolic 
extract on cardiovascular and haematological function in STZ-induced diabetic rats. 
1.8 Objectives 
The objectives of the study were to investigate the effects of Momordica balsamina methanolic 
extract on: 
 blood glucose concentration of STZ-induced diabetic rats 
 oxidative stress in the plasma, heart and kidney of STZ-induced diabetic rats 
 mean arterial blood pressure in STZ-induced diabetic rats 
 histological changes caused by hyperglycaemia on the cardiac muscle of STZ-induced 
diabetic rats 
 endothelial function (plasma angiotensin-II concentration) in STZ-induced diabetic rats 
 cardiac inflammation (heart cardiotrophin-I, heart and plasma CRP concentration) in 
STZ-induced diabetic rats 
 red blood cell structure (annexin-V) and function (RBC profile) in STZ-induced 
diabetic rats 
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Chapter 2 
Prologue 
Manuscript 1 
Hyperglycaemia has been shown to induce cardiovascular complications observed in diabetic 
patients, which have been shown to progress cardiac failure. Furthermore, current anti-diabetic 
agents have been associated with the advancement of cardiac disorders. Alternative treatment 
strategies are therefore needed. We have previously shown the anti-hyperglycaemic and reno-
protective effects of Momordica balsamina. Since improved renal function has been shown to 
be associated with improved cardiac function in diabetic animals, the current study, evaluated 
the effects of Momordica balsamina methanolic extract on selected cardiovascular function 
markers in a streptozotocin-induced diabetic rat model that has not been shown.  
The effects of Momordica balsamina methanolic extract on cardiovascular function in 
STZ-induced diabetic rats: effects on selected markers. 
 
 
The present manuscript was prepared for publication according to the Chemico-Biological 
Interaction journal’s guidelines to authors. see (Appendix 2). 
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The effects of Momordica balsamina methanolic extract on cardiovascular function in 
STZ-induced diabetic rats: effects on selected markers 
A. Ludidi1, A. Khathi1, N. H. Sibiya2, P. S. Ngubane1 
1School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
of KwaZulu-Natal, Private Bag X54001, Durban, 4000, South Africa 
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Abstract 
Background: Renal dysfunction and cardiovascular disorders are amongst the leading causes 
of deaths in Diabetes Mellitus (DM). Insulin administration has been associated with the 
progression of cardiac disorders due to hyperinsulinemia however, medicinal plants have been 
shown to have antidiabetic effects. We have previously shown the ameliorative effects of 
Momordica balsamina methanolic extract (MB) on renal dysfunction in streptozotocin (STZ)-
induced diabetic rats however, the cardiovascular effects have not yet been established. The 
study therefore, investigated the effects of MB on cardiovascular function in STZ-induced 
diabetic rats. 
Methods: Air-dried Momordica balsamina leaves were sequentially extracted with methanol 
to yield a methanolic extract. Short-term (5 weeks) effects of MB on cardiovascular function 
were assessed in STZ-induced diabetic rats treated twice daily with MB (250 mg kg-1 p.o.). 
Insulin (170 μg kg-1 s.c.) and metformin (500 mg kg-1 p.o.). Blood glucose concentration, body 
weight and blood pressure were monitored weekly for 5 weeks. Thereafter, the animals were 
sacrificed terminally, collecting blood and hearts for biochemical and histological analysis. 
Results: MB significantly decreased blood glucose concentration from week 3-5 by 
comparison with diabetic untreated animals. Treatment with MB reduced oxidative stress while 
improving the antioxidant status compared with untreated diabetic animals. MB treatment 
decreased CRP, CT-I and Ang-II concentrations by comparison with untreated diabetic animals. 
MB decreased MAP by comparison with untreated diabetic animals. Histopathological 
hypertrophy was observed in untreated diabetic rats that was ameliorated by the administration 
of MB. 
28 
 
Conclusions: The administration of MB protects against hyperglycemia-induced 
cardiovascular changes, which may reduce the risks of cardiovascular complications in diabetes 
mellitus. 
Key words: Cardiovascular disorder, C-reactive protein, oxidative stress, Momordica 
balsamina, cardiomyocyte, mean arterial pressure 
1 Introduction 
Diabetes mellitus (DM) is the leading non-communicable disease, which is associated with a 
significantly high morbidity and mortality rate and estimated to affect approximately 693 
million people by 2045 (1-3). Cardiovascular complications have been shown to contribute 
significantly to the total number of deaths caused by DM (4, 5). Metabolic syndromes, including 
DM, doubles the risk of developing cardiovascular complications, therefore diabetic patients 
have a two to five-fold greater mortality rate due to cardiovascular disease (6). Chronic 
hyperglycemia contributes to the progression of cardiovascular dysfunction via increased 
oxidative stress and endothelial dysfunction (7, 8). Oxidative stress due to the overproduction 
of superoxide induces an alteration in the morphology and function of the cardiomyocyte as 
shown by cardiac hypertrophy which is marked by an increase in secretion of cardiotrophin-I 
(9). Furthermore, chronic inflammation is promoted and thus the increase in proinflammatory 
cytokines such as tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP) and 
cardiotrophin-I (CT-I) which indicate cardiac damage (10, 11). In addition, hyperglycemia 
induced reactive oxygen species (ROS) production results in the reduction in the bioavailability 
of nitric oxide (NO) (12). NO decline is the result of the reduced expression of endothelial cell 
NO synthase (eNOS), inefficient eNOS activation, insufficient substrate or cofactors for eNOS 
and accelerated degradation of NO2 by ROS (13, 14). Furthermore, endothelial dysfunction is 
accompanied by increased vasoconstrictors including angiotensin-II (15, 16). The pathology of 
endothelial dysfunction therefore, results in increased arterial stiffness and increased arterial 
pressure (17). In addition, dyslipidemia has been associated with an increase in atherosclerotic 
plaque formation, which narrows the vascular lumen, therefore raising blood pressure (18). 
The long-term increase in blood pressure is associated with cardiac myopathy, cardiac 
hypertrophy and eventually cardiac failure (19, 20). 
There are however, conventional treatments to manage diabetes and associated complications 
with insulin being the mainstay treatment (21). The administration of insulin as a bolus 
however, has been shown to be associated with hyperinsulinemia, increased sodium retention 
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and therefore increased blood pressure (22). Moreover, insulin and oral hypoglycemic agents 
have been shown to deteriorate liver function and increase plasma volume which is of concern 
in patients with congestive heart failure (22, 23). These challenges have led to the investigation 
of alternative therapeutic interventions with less undesirable effects. 
Traditionally, various plants have been shown to alleviate diabetes-associated complications. 
Of interest to our study is Momordica balsamina, commonly known as “Intshungu”, a plant 
widespread in Namibia, Botswana, Swaziland and all provinces of South Africa (24). The plant 
has been reported to possess hypoglycemic effects and improves renal function in 
streptozotocin (STZ)-induced diabetic rats (25, 26). Despite these developments, the 
cardiovascular effects of this plant remain elusive hence the interest in investigating the effects 
of MB on cardiovascular function in STZ-induced diabetic rat model. We envisaged that 
monitoring blood glucose concentration, mean arterial pressure (MAP), oxidative stress and 
inflammatory status may provide a holistic insight on the effects of cardiovascular function as 
a result of MB administration (25). 
2 Materials and methods 
2.1 Drugs and chemical reagents: 
Streptozotocin (Sigma Aldrich Chemical Company, Missouri, St Louis, USA); glucose 
(C6H12O6),calcium chloride (CaCl2), citric acid, monosodium citrate (Merck chemicals (Pty) 
Ltd Wadeville, Johannesburg, South Africa); metformin, dimethyl sulphoxide (Sigma-Aldrich, 
St Louis, Missouri, United States of America); insulin (NovoRapid pen refill, Novordisk Pty 
Ltd, Sandton, South Africa). 
2.2 Plant extraction 
The leaves of Momordica balsamina were identified and authenticated by Professor H Baijnath, 
the former chief taxonomist/curator of the University of KwaZulu-Natal department of botany. 
The extraction of Momordica balsamina leaves were performed in the School of laboratory 
Medicine and Medical Sciences, at the University of KwaZulu-Natal, Westville Campus, using 
a previously validated protocol formerly reported by our laboratory (27). Briefly, the air-dried 
Momordica balsamina leaves (1.15kg) were sequentially extracted by cold percolation with 
methanol (95%, 6.9L) for 24 h. The methanolic extract was recovered from the mixture and 
methanol was added to the pulp for further extraction. To maximize the extraction process to 
increase the yield (609g), the process was repeated three times. The three extracts were 
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combined to yield a concentrated methanolic extract at a reduced pressure (22-26mmHg) and 
temperature of 45-60 ºC. 
2.3 Animals 
Male Sprague-Dawley (SD) rats (250 -300 g, n=30) bred and housed in the Biomedical 
Research Unit (BRU) of University of KwaZulu-Natal were used in the present study. The 
animals were maintained under standard laboratory conditions of constant temperature (22±2 
ºC), CO2 content of ˂5000 p.m., relative humidity of 55±5% and illumination (12 h light/dark 
cycles) and the noise levels of less than 65 decibels and ad libitum access to food and water. 
Procedures involving animals and their care were conducted in conformity with the institutional 
guidelines of the University of KwaZulu-Natal (AREC/023/017M). Individual rats were housed 
in Makrolon polycarbonate metabolic cages (Techniplast, Labotec, South Africa) and were 
acclimatized in metabolic cages for 5 days before commencement of the study. 
2.4 Induction of diabetes mellitus 
The induction of type 1 diabetes mellitus by a single intraperitoneal injection of 60 mg kg-1 
streptozotocin, which was freshly prepared in 0.1 M citrate, buffer (pH 4.5). Control group 
received the vehicle, citrate buffer through the same route. Animals that presented glucosuria 
after 24 h, when tested by urine strips (Rapidmed Diagnostics, Sandton, South Africa) were 
considered diabetic. Seven days after the induction of diabetes, animals that had a blood glucose 
concentration greater than 20 mmol L-1 were considered as having stable diabetes. 
2.5 Experimental design 
To study the short-term effects of Momordica balsamina methanolic extract (MB) on the 
cardiovascular system over 5 weeks of treatment, experimental rats were divided into separate 
groups of non-diabetic (group 1) and STZ-induced diabetic (group 2-5) male Sprague-Dawley 
rats, with six rats per group. Group 1 was treated with the drug vehicle DMSO to serve as a 
negative control. Group 2 was treated with Momordica balsamina methanolic extract (250 mg 
kg-1, p.o.). Positive controls in Group 3 and 4 were treated with insulin (175 μg kg-1, s.c.) and 
metformin (500 mg kg-1, p.o.), respectively. Non-diabetic animals in Group 5 served as absolute 
control. MB was administered twice daily at 09h00 and 15h00. Food and water intake, body 
weight, mean arterial blood pressure (MAP) and blood glucose concentration were monitored 
over the 5-week period. MAP was measured using the non-invasive tail cuff method with 
photoelectric sensors (IITC Model 31 Computerised Blood Pressure Monitor, Life Sciences, 
Woodland Hills, California, USA) as previously described (28), while blood glucose 
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concentrations were measured via the tail pricking method. All parameters were assessed every 
3rd day at 09:00 am for the duration of experimental period. 
2.6 Tissue sample harvesting 
At the end of the 5-week experimental period, all animals were sacrificed by exposing to 
halothane via a gas anesthetic chamber (100 mg kg-1) for 3 minutes (Biomedical Resource Unit, 
UKZN, Durban, South Africa). Thereafter, blood was collected by cardiac puncture (RBCP) 
into individual pre-cooled heparinized container and centrifuged (Eppendorf centrifuge 5403, 
Germany) at 4 °C, 503 g for 15 minutes and separated plasma were stored at -80 in a Bio Ultra 
freezer (Snijers Scientific, Holland) for hormonal analysis. The heart tissues were removed and 
weighed before snap freezing in liquid nitrogen and then stored in a BioUltra freezer (Snijers 
scientific, Tilburg, Netherlands) -80 °C until use. 
2.7 Biochemical analysis 
2.7.1 C-reactive protein and angiotensin-II measurement 
Heart and plasma C-reactive protein (CRP) and plasma angiotensin-II (Ang-II) were analysed 
using separate specific ELISA kits (Elabscience and Biotechnology, WuHan) that use the 
Sandwich-ELISA method. Kits included micro ELISA plates, which were coated with antibody 
specific to CRP and angiotensin-II, respectively. Standards and samples were pipetted into the 
appropriate wells of the micro ELISA plate and incubated for 90 minutes. The plate relevant 
biotinylated detection antibody (100 µL) was then added and incubated for 60 minutes. Avidin-
Horseradish Peroxidase (HRP) conjugate (100 µL) was added to each micro-plate well and 
incubated for 30 minutes. Unbound components were washed out. Substrate solution (100 µL) 
was added to each micro-plate well. After incubating for a further 15 minutes, the stop solution 
(50 µL) was added. The optical density was measured using a Nano spectrophotometer (BMG 
Labtech, Ortenburg, Baden-Wurttemberg, Germany) at the wavelength of 450 nm. The 
concentration of the samples was extrapolated from the respective standard curves. 
2.7.2 Cardiotrophin-I measurement 
Heart cardiotrophin-I (CT-I) was analysed using a separate specific CLIA kit (Elabscience and 
Biotechnology, WuHan) that uses the Sandwich- CLIA method. The kit included a micro CLIA 
plate, which was coated with an antibody specific to CT-I. Standards and samples were pipetted 
into the appropriate wells of the micro CLIA plate and incubated for 90 minutes. The plate 
relevant biotinylated detection antibody (100 µL) was then added and incubated for 60 minutes. 
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Avidin-Horseradish Peroxidase (HRP) conjugate (100 µL) was added to each micro-plate well 
and incubated for 30 minutes. Unbound substances were washed out. Substrate mixture solution 
(100 µL) was added to each micro-plate well. After incubating for not more than 5 minutes 
protecting from the light the relative light unit (RLU) was measured using the GloMax® 96 
Microplate Luminometer (BMG Labtech, Ortenburg, Baden-Wurttemberg, Germany). The 
concentration of the samples were extrapolated from the respective standard curves.  
2.7.3 Oxidative stress 
To establish the effects of treatment on oxidative stress in the plasma and heart muscle, levels 
of malondialdehyde (MDA), a commonly known marker of oxidative stress, were measured in 
untreated and treated experimental animals using a biochemical assay as shown below. The 
antioxidant defense enzymes: superoxide dismutase (SOD) and glutathione peroxidase (GPx) 
were also measured in untreated and treated experimental animals (29). 
2.7.3.1 Malondialdehyde measurement  
Heart tissues (50 mg) were homogenized in 500 µL of 0.2% phosphoric acid, respectively. The 
homogenate was centrifuged at 400 x g for 10 min. Thereafter, 400 µL of the homogenate and 
100 µL plasma were supplemented with 400 µL 2% phosphoric acid and then separated into 
three glass tubes, each receiving equal volumes of the solution. Subsequently, 200 µL of 7% 
phosphoric acid was added into all glass tubes followed by the addition of 400 µL of 
thiobarbituric acid (TBA)/butylated hydroxytoluene (BHT) into two glass tube (sample tests) 
and 400 µL of 3 mM hydrochloric acid (HCl) into the third glass tube (blank). To ensure an 
acidic pH of 1.5, 200 µL of 1 M, HCl was added to sample and blank test tubes. All solutions 
were heated at 100 ̊C for 15 min, and allowed to cool to room temperature. Butanol (1.5 mL) 
was added to the cooled solutions; the sample tests were vortexed for 1 min to ensure rigorous 
mixing and allowed to settle until two phases are distinguished. The butanol phase (top layer) 
was transferred to Eppendorf tubes and centrifuged at 13,200 x g for 6 min. The samples were 
aliquoted into a 96-well microtiter plate in triplicate and the absorbance was read at 532 nm 
(reference 600 nm) on a BioTek µQuant spectrophotometer (Biotek, Johannesburg, South 
Africa). The absorbance from these wavelengths were used to calculate the concentration of 
MDA using Beer’s Law. 
Concentration of MDA (mM) 
=
Average Absorbance
Absorption coefficient (156 mmo𝑙−1)
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2.7.3.2 Superoxide dismutase and glutathione peroxidase measurement 
Superoxide dismutase (SOD) and glutathione peroxide (GPx) in both the plasma and heart 
tissues were analysed using separate specific ELISA kits (Elabscience and Biotechnology, 
WuHan) that use the Sandwich-ELISA method. Kits included micro ELISA plates that were 
coated with antibody specific to SOD and GPx, respectively. Standards and samples were 
pipetted into the relevant wells of the micro ELISA plate and incubated for 90 minutes. The 
plate relevant biotinylated detection antibody (100 µL) was then added and incubated for 60 
minutes. Avidin-Horseradish Peroxidase (HRP) conjugate (100 µL) was added to each micro-
plate well and incubated for 30 minutes. Unbound components were washed out. Substrate 
solution (100 µL) was added to each micro-plate well. After incubating for a further 15 minutes, 
the stop solution (50 µL) was added. The optical density was measured using a Nano 
spectrophotometer (BMG Labtech, Ortenburg, Baden-Wurttemberg, Germany) at the 
wavelength of 450 nm. The concentration of the samples was extrapolated from the respective 
standard curves. 
2.8 Histology of the heart 
Heart tissues were fixed in formalin overnight, paraffin embedded and processed for sectioning. 
0,5 µM sections were made and stained with hematoxylin and eosin (H&E) to analyze the 
cardiomyocyte size and the arrangement of cardiomyocyte myofibres using Leica microsystems 
for analysis. 
For the assessment of histological cardiovascular changes after treatment, the heart tissues of 
non-diabetic, untreated STZ-induced diabetic rats and treated STZ-induced diabetic rats were 
dissected out for fixation with 10% formaldehyde solution at the end of the 5-week 
experimental period. Excess formalin was removed from the heart tissues by rinsing with water. 
The heart tissues were then dehydrated in 70%, 80%, 90%, as well as 100% ethanol for 2, 2, 3 
and 2 minutes respectively. To remove the alcohol, the tissues were then submerged in xylene 
rendering the tissue translucent. In preparation for sectioning, the tissues were embedded in 
wax blocks which were sectioned at a thickness of 3-5µm using a rotary microtome (Robert-
Bosch-Straße, Walldorf, Baden-Württemberg, Germany). Sectioned tissues were then mounted 
onto clean slides and dried by placing them on a Ransom warming plate. 250 ml of xylene was 
then used to de-paraffinize the sections twice for 3 min each time. The rehydration of tissue 
sections in decreasing concentrations of 100%, 90%, 70% and 50% ethanol for 2 minutes each 
time in preparation for staining. The tissue slides were then flooded with hematoxylin, using a 
Pasteur pipette and allowed to stand for 5 minutes and the slide was tilted to remove the 
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hematoxylin stain. Using tap water, the slides were then gently flood with a Pasteur pipette 
three times or until the sections stained purple turned blue. Pasteur pipette was used over the 
tissue sections to drop the Eosin stain and left to stand for 3-5minutes. Tap water was used to 
rinse off the residual eosin on the tissue sections/slide. Tissue slides were then dehydrated by 
submerging the slides in increasing 90% and 100% ethanol. Sections were then cleared with 
then cleared with xylene in preparation for permanent mounting by dropping distyrene 
plasticizer xylene (DPX) mounting glue directly over the tissue section using an applicator, then 
covering with a cover slip. The sections were allowed to dry overnight. The processed tissue 
sections were then visualized and captured using a Leica Scanner, SCN400 and Slide Path 
Gateway LAN software for analysis (Leica Microsystems CMS, Wetzlar, Germany). 
2.9 Statistical analysis 
All data are expressed as means ± standard error of means (SEM). GraphPad Prism Instat 
Software (version 5.00, GraphPad Software, San Diego, California, USA) was used to perform 
statistical analysis. Blood glucose and MAP were analysed using analysis of variance 
(ANOVA) followed by Bonferroni post hoc test. ANOVA was used to analyze terminal 
parameters to compare the differences between control and experimental groups. Values of 
p<0.05 were regarded statistical significant between the compared groups. 
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Results 
3.1 Blood glucose concentration 
Figure 1 shows blood glucose concentration of non-diabetic control (NC), diabetic control (DC) 
and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1) metformin (MTF) 
and insulin (INS) over an experimental period of 5weeks. The untreated STZ-induced diabetic 
animals sustained a significantly high blood glucose concentration over the period of 5 weeks 
by comparison with non-diabetic control α (DC vs NC, p<0.05, Figure 1). Treatment with MB, 
insulin and metformin showed a significant decrease in blood glucose from week 3,4 and 5 by 
comparison with the diabetic control animals *(MB vs DC, p<0.05, Figure 1). Blood glucose 
concentrations of animals treated with insulin significantly decreased at week 5 by comparison 
with animals treated with MB λ (INS vs MB, p<0.05, Figure 1). 
Figure 1: Comparison of blood glucose concentration in non-diabetic control (NC), diabetic 
control (DC) and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1), 
metformin (MTF) and insulin (INS) over the period of 5 weeks. Values are presented as means 
and vertical bars indicate SEM (n=6 in each group). α p˂0.05 by comparison with non-diabetic 
control animals. * p˂0.05 by comparison with diabetic control animals. λ p˂0.05 by comparison 
with MB treated animals. 
1 2 3 4 5
0
5
10
15
20
25
30
35 
*
*
*
*
*
**
*
*

NC
DC
INS
MTF
MB
weeks
B
lo
o
d
 g
lu
co
se
(m
m
ol
/L
)
36 
 
3.2 Mean arterial blood pressure 
Figure 2 shows the mean arterial pressure (MAP) of non-diabetic control (NC), diabetic control 
(DC) and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1), metformin 
(MTF) and insulin (INS) over an experimental period of 5 weeks, measured 24 hours after 
treatment. The diabetic control group showed a significantly high MAP throughout the 5-week 
experimental period by comparison with non-diabetic control α (DC vs NC, p<0.05, Figure 2). 
However, treatment with MB decreased MAP similarly to metformin and insulin from week 3 
to 5 by comparison with the untreated STZ-induced diabetic rats *(MB vs DC, p<0.05, Figure 
2), while insulin significantly increased MAP from week 3 to week 5 by comparison with 
metformin and MB λ (INS vs MTF and MB, p<0.05, Figure 2). 
 
Figure 2: Comparison of MAP in non-diabetic control (NC), diabetic control (DC) and diabetic 
animals treated with Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin 
(INS) over the period of 5 weeks. Values are presented as means and vertical bars indicate SEM 
(n=6 in each group). α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by 
comparison with diabetic control animals. λ p˂0.05 by comparison with MB treated animals. 
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3.3 Heart to body weight ratio 
Table 1 compares the heart to body weight ratios of non-diabetic control (NC), diabetic control 
(DC) and diabetic animals treated with MB (250 mg kg-1), metformin (MTF) and insulin (INS) 
over a 5-week treatment period. Diabetic control rats exhibited an increase in heart to body 
weight ratio compared with non-diabetic control rats at the end of the 5-week experiment α (DC 
vs NC, p<0.05). MB administration similarly to standard drugs, decreased heart to body weight 
ratio compared with STZ-induced diabetic control rats at the end of the 5-week experimental 
period *(MB vs DC, p<0.05). 
 
Table 1: Comparisons of the (H/B) ratios of non-diabetic control (NC), diabetic control (DC) 
and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) 
and insulin (INS). Values are expressed as mean ± SEM (n=6 in each group).  
 
Experimental 
groups 
Final body weight (g) Hearts weight (g) H/B ratio (%) 
NC 307.00 ± 7.66 1.22 ± 0.08 0.39 ± 0.02 
DC 169.17 ± 4.75   α 1.22 ± 0.06 0.72 ± 0.04 α 
INS 281.92 ± 2.39   * 1.04 ± 0.05 0.37 ± 0.02 * 
MTF 256.67 ± 10.17 * 1.12 ± 0.11 0.43 ± 0.04 * 
MB 243.83 ± 5.39   * 1.08 ± 0.03 0.44 ± 0.02 * 
α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by comparison with 
diabetic control. 
3.4 MDA, SOD and GPx concentrations 
Table 2 Depicts the comparisons of MDA, SOD and GPx concentrations in both the heart and 
plasma of non-diabetic control (NC), diabetic control (DC) and diabetic animals treated with 
Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS) after 5 weeks 
of treatment. Untreated STZ-diabetic heart and plasma tissues presented with increased 
concentrations of MDA by comparison to untreated non-diabetic rats α (DC vs NC, p<0.05). In 
addition, GPx concentrations in the plasma of untreated STZ-induced diabetic rats significantly 
decreased by comparison with non-diabetic animals α (DC vs NC, p<0.05). The plasma MDA 
concentrations of MB treated animals similarly to standard drugs decreased by comparison to 
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untreated STZ-induced diabetic rats *(MB vs DC, p<0.05). Furthermore, GPx concentrations 
in the plasma of MB treated animals similarly to standard drugs increased by comparison to 
untreated non-diabetic rats *(MB vs DC, p<0.05). However, heart GPx concentrations of MB 
treated animals significantly decreased by comparison with untreated STZ-diabetic rats *(MB 
vs DC, p<0.05). Furthermore, heart and plasma SOD concentrations of MB treated animals, 
significantly decreased by comparison with untreated diabetic animals *(MB vs DC, p<0.05). 
 
Table 2: Comparison of MDA, SOD and GPx concentrations of both plasma and heart tissues 
of non-diabetic control (NC), diabetic control (DC) and diabetic animals treated with 
Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS). Values are 
presented as means ± SEM (n=6 in each group). 
 
 Plasma Heart 
MDA (μmol/g protein) NC 0.68 ± 0.12 1.21 ± 0.04 
DC 9.37 ± 1.19 α 1.38 ± 0.09 
INS 0.54 ± 0.03 * 1.21 ± 0.02 
MTF 0.35 ± 0.06 * 1.26 ± 0.12 
MB 2.48 ± 0.05 * 1.15 ± 0.10 * 
  
GPx Concentration (ng/mL) NC 1.44 ± 0.03 1.14 ± 0.01 
DC 0.21 ± 0.04 α 1.37 ± 0.09 
INS 0.83 ± 0.01 * 1.39 ± 0.03 
MTF 1.67 ± 0.01 * 1.23 ± 0.06 
MB 1.06 ± 0.04 * 0.79 ± 0.05 
  
SOD Concentration (ng/mL) 
 
NC 35.39 ± 0.63 65.92 ± 0.98 
DC 33.55 ± 0.27 63.21 ± 1.92 
INS 31.68 ± 2.76 66.69 ± 1.11 
MTF 29.85 ± 2.44 65.17 ± 1.17 
MB 23.63 ± 0.87 33.55 ± 0.27 
α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by comparison with 
diabetic control. 
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3.5 CRP and CT-I concentrations 
Table 3 shows the comparisons heart and plasma CRP and heart CT-I concentrations of non-
diabetic control (NC), diabetic control (DC) and diabetic animals treated with Momordica 
balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS) after 5 weeks of treatment. 
Heart and plasma CRP with heart CT-I concentrations of untreated STZ-diabetic animals 
significantly increased by comparison with non-diabetic rats α (DC vs NC, p<0.05). 
Furthermore, insulin sustained a high heart and plasma CRP and heart CT-I concentration 
similarly to untreated STZ-diabetic animals *(INS vs DC, p<0.05). However, MB similarly to 
metformin, significantly decreased heart and plasma CRP and heart CT-I concentrations of 
untreated STZ-diabetic animals by comparison to untreated STZ-induced diabetic rats (MB vs 
DC, p<0.05). 
 
Table 3: Comparison of heart and plasma CRP and heart CT-I concentrations in non-diabetic 
control (NC), diabetic control (DC) and diabetic animals treated with Momordica balsamina 
(MB) (250 mg kg-1), metformin (MTF) and insulin (INS). Values are presented as means ± 
SEM (n=6 in each group). 
 
Experimental groups CRP (ng/mL) CT-I (pg/mL) 
Plasma Heart Heart 
ND 0.38 ± 0.01 5.61 ± 0.65 9.13 ± 0.85 
DC 0.43 ± 0.01 α 14.31 ± 0.38 α 35.01 ± 0.26 α 
INS 0.64 ± 0.03 * 15.66 ± 0.18 * 37.60 ± 1.62 * 
MTF 0.42 ± 0.03 * 6.57 ± 0.21   * 11.14 ± 1.62 * 
MB 0.32 ± 0.01 * 7.11 ± 0.72   * 9.73 ± 0.08   * 
α p˂0.05 by comparison with non-diabetic control animals.* p˂0.05 by comparison with 
diabetic control. 
3.6 Ang-II concentrations 
Table 4 displays the comparisons of plasma angiotensin-II (Ang-II) of non-diabetic control 
(NC), diabetic control (DC) and diabetic animals treated with Momordica balsamina (MB) (250 
mg kg-1), metformin (MTF) and insulin (INS) after 5 weeks of treatment. Plasma angiotensin-
II concentrations of untreated STZ-diabetic rats significantly increased by comparison with 
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non-diabetic animals α (DC vs NC, p<0.05). However, MB treated animals similarly to insulin 
and metformin treated animals exhibited a significantly decreased plasma Ang-II 
concentration*(MB vs DC, p<0.05). 
 
Table 4: Comparison of plasma Ang-II concentrations of non-diabetic control (NC), diabetic 
control (DC) and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1), 
metformin (MTF) and insulin (INS). Values are presented as means ±SEM (n=6 in each group). 
 
Experimental groups Plasma Ang-II (ng/mL) 
ND 3.98 ± 0.04 
DC 4.34 ± 0.05 α 
INS 4.01 ± 0.04 * 
MTF 3.81 ± 0.06 * 
MB 3.77 ± 0.09 * 
α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by comparison with 
diabetic control. 
3.7 Histology of the heart 
Figure 3 are the H & E photomicrographs illustrating the effects of treatment on the morphology 
of the heart tissue in (NC), diabetic control (DC) and diabetic animals treated with Momordica 
balsamina (MB) (250 mg kg-1) metformin (MTF) and insulin (INS) after an experimental period 
of 5weeks. Photomicrograph of the non-diabetic untreated group showed single, oval and 
centrally located nuclei (N) of the cardiomyocytes. The cardiac myofibres (MF) in the non-
diabetic control group were arrangement in a regular pattern (A). Nuclei of the cardiomyocytes 
in the diabetic control group (B) showed deformation in sizes and shapes. Moreover, the cardiac 
myofibres in the diabetic untreated group (B) showed disarrayed patterns compared to the non-
diabetic untreated group (A). Nuclei of the cardiomyocytes in the insulin treated group (C) 
showed deformation in size and shape. Additionally, the insulin treated group (C) showed 
disarrayed cardiac myofibres similarly to the diabetic control group (B). The nuclei of the 
cardiomyocytes in the metformin treated group (D) showed an improvement in size and shape 
by comparison to the diabetic control group (B). In particular, the nuclei were single, oval and 
centrally located similarly to the cardiomycytes in the non-diabetic control group (A). The 
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arrangement of the cardiac myofibres in the metformin treated group improved to near normal 
compared to the non-diabetic control group (A). Nuclei of the cardiomyocytes in the MB treated 
group (E) showed an improvement in size and shape compared to the diabetic control group 
(B). Moreover, the nuclei were single, oval and centrally located similarly to the cardiomycytes 
in the non-diabetic control group. Arrangement of cardiac myofibres in MB treated group (E) 
improved to a near normal pattern compared to the non-diabetic control group (A). 
Magnification 20X-100 µm. 
 
Figure 3: H & E photomicrographs illustrating cardiac tissue morphology in non-diabetic 
control (NC), diabetic control (DC) and diabetic animals treated with Momordica balsamina 
(MB) (250 mg kg-1), metformin (MTF) and insulin (INS) after 5 weeks of treatment. 
Magnification 20X-100 µm. 
4 Discussion 
The present study investigated whether treatment with a methanolic extract of Momordica 
balsamina ameliorates cardiovascular dysfunction commonly observed in diabetic patients and 
modelled in streptzotocin (STZ)-induced diabetic rats. We have previously shown that 
Momordica balsamina possess antihyperglycemic properties and improves kidney function. 
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Here in this study, Momordica balsamina improves oxidative stress, cardiovascular structure 
and function in STZ-induced diabetic rats. 
Chronic hyperglycemia which is a characteristic in DM alters cardiovascular function and 
indeed STZ administration resulted in sustained hyperglycemia throughout the study due to the 
obliteration of pancreatic β-cells as shown in previous studies (30, 31). Administration of MB 
however, decreased glycemia in STZ-diabetic rats. Medicinal plants such as Momordica 
charantia Linn which is in the same family as Momordica balsamina have been shown to 
possess antihyperglycemic phytochemicals such as flavonoids, cucurbitane triterpenoids and 
phytosterols (32). Flavonoids have been shown to inhibit the activity of α-amylase and α-
glucosidase in vitro, delaying postprandial glucose absorption (33). In addition, flavonoids 
have been shown to inhibit glucose transport through the inhibition of intestinal sodium-glucose 
co-transporters (34, 35). Interestingly, Momordica balsamina has been reported in our 
laboratory to decrease food intake of STZ-induced diabetic rats (26). Momordica balsamina 
therefore may maintain glycemic control through its antihyperglycemic effects similarly to 
other medicinal plants such as Tripterygium wilfordii possibly via delaying postprandial 
glucose absorption, thus activating the release of appetite modulation hormones such as 
cholecystokinin (CCK) and peptide YY(PYY) to inhibit feeding thus decreasing ghrelin 
secretion (36, 37).   
An improvement in glycemic control has been shown to attenuate oxidative stress-induced 
debilitating cardiovascular complications in diabetic patients and experimental animals (38). 
Evidently, STZ-diabetic rats in the present study maintained increased oxidative stress, which 
was associated with the dysregulation of the antioxidant defense system, inflammation and 
endothelial function. The antioxidant defense system is adapted to scavenge ROS to minimize 
alteration in cell structure and function (39-41). It has been documented that hyperglycemia-
induced glycation of proteins including superoxide dismutase and glutathione peroxide alters 
their structure reducing their efficiency (42). In agreement with previous studies, the 
suppression of GPx which detoxifies a ROS product- hydrogen peroxide- to water, was 
observed in our STZ-induced diabetic rats (43). This may be correlated with a rise in 
hyperglycemia-induced enzyme glycation, increasing oxidative stress (44, 45). Interestingly, 
MB administration improved the antioxidant status possibly through increasing GPx that 
scavenges ROS although SOD was not improved possibly due to glycation of this enzyme 
augmenting loss of enzyme activity. In addition, an increase in oxidative stress has been shown 
to dysregulate inflammation evidenced in the increase in CRP, which is a marker for increased 
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cardiovascular dysfunction in the STZ-induced diabetic animal. Moreover, Momordica 
balsamina attenuated the rise in CRP associated with the morphological and functional 
alteration of cardiomyocytes. 
The progression of cardiac dysfunction was further evidenced in the present STZ-induced rats 
which may be attributed to the increase in the polyol pathway, resulting in the accumulation of 
sorbitol which induces osmotic stress in cardiomyocytes (46, 47). Osmotic stress activates the 
extracellular signal-regulated protein kinase and protein kinase C which are associated with cell 
growth, hence hypertrophy which may account for alteration in cardiomyocyte structure (48). 
Interestingly, MB attenuated the metabolic injury specifically to the cardiac muscle as observed 
by the restoration in the histological architecture of cardiomyocyte that may be associated with 
the decrease in oxidative stress, marked by MDA (49-51). This is in harmony with previous 
findings showing that an improvement in oxidative stress improves cardiac function (52, 53). 
Hyperglycemia has been associated with an increase in MAP, which may be attributed to kidney 
dysfunction due to the increase in renal sodium reabsorption increasing blood volume in 
synergy with increased vasoconstrictors including angiotensin-II that may have stimulated 
hyperglycemia-induced collagen synthesis in the vasculature, consequently narrowing and 
stiffening the blood vessels (54). Resistance of blood flow therefore may have ensued hence an 
alleviated MAP as observed in the present STZ-induced diabetic animals (55). The increase in 
MAP forces the cardiac muscle to stretch, activating the release of CT-I by cardiac fibroblasts 
via the stimulation of the JAK/STAT pathway (56). JAK/STAT pathway activation through 
CT-I signals the expression and transcription of genes involved in immunity, proliferation and 
differentiation in the cardiomyocytes nucleus as observed in our STZ-induced diabetic animals 
(57, 58). An elevation in CT-I of STZ-induced diabetic animals therefore exacerbates cardiac 
dysfunction. Additionally, the increase in collagen synthesis in the cardiac muscle dysregulates 
the synchronous contractility of the cardiomyocytes hence cardiac myopathy (54, 59). In the 
present study, elevated MAP of STZ-induced rats coincides with the increase in heart to body 
weight ratio, suggesting cardiac hypertrophy. However, MB attenuated the rise in MAP 
possibly through decreasing Ang-II decreasing cardiac overload and mechanical stretch of the 
cardiac muscle, hence a decrease in CT-I. Additionally, the ability of MB to improve heart to 
body weight ratio similarly to metformin, may have improved cardiac hypertrophy. In addition, 
we have previously reported that MB improves kidney function and a decrease in MAP may be 
attributed to the restoration of electrolyte handling (26). Our results are in line with literature 
as medicinal plants such as Prosopis gradulosa have been shown to possess hypotensive, anti-
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ischemic effects in addition to an increased cardiomyocyte insulin sensitivity. Furthermore, 
plants such as Hibiscus subdariffa have been shown to possess lipid lowering activity and 
reverse cardiac hypertrophy (60). As predicted, treatment with insulin in this study also showed 
an increase in MAP as seen in STZ-induced diabetic rats, as insulin is mitogenic and promotes 
proliferation of cells, which was associated with the observed cardiac hypertrophy although the 
heart to body weight ratio was decreased. In addition, supraphysiological administration of 
insulin to diabetic patients has been shown to increase sodium reabsorption associated with 
hyperinsulinemia and edema consequently contributing to the alleviated MAP which is 
associated with cardiac hypertrophy, progressing cardiovascular complications (61). 
The present study is in agreement with the medicinal use of MB and provides evidence that it 
may delay the onset of the progression of cardiovascular complications in diabetic patients. In 
addition, since Momordica balsamina is widely spread in developing countries such as South 
Africa, this study may provide evidence that MB may indeed be a beneficial and easily 
accessible management strategy for diabetic patients. 
5 Conclusion 
Momordica balsamina administration attenuates hyperglycemia accompanied by an 
improvement in the antioxidant status. Furthermore, the administration of the extract 
ameliorated an increase in MAP, cardiac hypertrophy and inflammatory markers in STZ-
induced diabetic rats. The observations further highlight the cardiovascular risk associated with 
insulin administration. In conclusion, the observations from this study support the use of 
medicinal plants as an alternative for the management of diabetes related complications. 
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Chapter 3 
Prologue 
 
Manuscript 2 
 
The haematological changes associated with hyperglycaemia have been shown to aggravate 
cardiovascular complications in diabetic patients. In addition, conventional treatment has been 
shown to alter haematological function, which eventually, advances cardiovascular 
dysfunction in diabetic patients. Hence the need of alternative treatment strategies. We have 
previously shown the anti-hyperglycaemic and reno-protective effects of Momordica 
balsamina in STZ-induced diabetic rats which may benefit patients with hyperglycaemia-
induced haematological changes associated with cardiovascular dysfunction. The effects of 
MB on haematological function in STZ-induced diabetic rats however, have not been 
established. The present study therefore investigated the effects of Momordica balsamina 
methanolic extract on haematological function in STZ-induced diabetic rats with specific 
interests on red blood cell function. This is in an effort to establish the mechanisms by which 
MB may alleviate cardiovascular dysfunction in diabetic animal models. 
The effects of Momordica balsamina methanolic extract on haematological function in 
STZ-induced diabetic rats: Effects on selected markers. 
 
The present manuscript was prepared for publication according to the Biomedicine and 
pharmacotherapy journal’s guidelines to authors. see (Appendix 3). 
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Abstract 
Background: Chronic hyperglycaemia-induced haemanetic changes increases the risk of 
cardiovascular complications in diabetic patients. The administration of Insulin injection as a 
bolus is accompanied with increased blood viscosity, which is not recommended for patients 
with congestive heart failure. Momordica balsamina (MB) methanolic extract has previously 
been shown to possess anti-hyperglycaemic and renal dysfunction ameliorative effects; 
however, the haematological effects of MB have not been shown. The current study therefore, 
investigated the short-term effects MB on selected haematological parameters in streptozotocin 
(STZ)-induced diabetic rats. Methods: Briefly, the air-dried Momordica balsamina leaves 
were sequentially extracted with methanol to yield a methanolic extract. STZ-induced diabetic 
rats were divided into untreated and treated groups with insulin (170 μg kg-1 s.c.) and 
metformin (500 mg kg-1 p.o.) MB (250 mg kg-1 p.o.). MB was administered twice daily for the 
5-week experimental period. Blood glucose concentration was monitored weekly. Animals 
were sacrificed terminally. Blood and kidneys were collected for haematological and 
biochemical analysis respectively. Results: Treatment with MB significantly decreased blood 
glucose concentration and improved erythropoietin secretion, thus significantly increasing red 
blood cell production in treated diabetic animals by comparison to untreated animals. MB also 
significantly improved haemoglobin concentrations and moderately increased erythrocyte 
indices specifically, mean cell volume (MCV), mean cell haemoglobin concentration (MCHC) 
and mean corpuscular haemoglobin (MCH) to no significance by comparison to untreated 
diabetic animals. MB treatment decreased the oxidative stress evoked by the induction of 
diabetes while improving the antioxidant status of treated animals by comparison to untreated 
animals respectively. Conclusions: Administration of Momordica balsamina methanolic 
extract protects against the injurious haematological changes induced by hyperglycaemia, 
which may reduce the risks of cardiovascular complications. Key words: Erythropoiesis, 
oxidative stress, Momordica balsamina, streptozotocin, hyperglycaemia 
Introduction  
 
Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycaemia (1). Sustained 
hyperglycaemia has been shown to progress the pathology of cardiac damage through 
haemanetic changes which include haemolysis of erythrocytes, consequent decrease in red 
blood cell count and haemoglobin concentrations which is associated with the development of 
diabetic anaemia and increases the risk of cardiovascular complications if left untreated (2). 
Hyperglycaemia has been shown to increase the probability of the non-enzymatic glycosylation 
of red blood cell membrane proteins resulting in the non-specific aggregation of protein 
molecules and alters the protein-protein and protein-lipid interaction leading to the 
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modification and disrupts the integrity/and symmetry of the erythrocyte membrane (3, 4). A 
loss of membrane symmetry increases erythrocyte aggregation, decreases mobility of the red 
blood cells and increases blood viscosity, which consequently elevates arterial pressure, thus 
increasing cardiovascular complications (5-7). In diabetic patients, sustained hyperglycaemia 
results in an increase in reactive oxygen species (ROS) and lipid peroxidation (8). Furthermore, 
chronic hyperglycaemia induced ROS production such as H2O2, crosses the erythrocyte 
membrane and oxidizes heme proteins, which have been shown to lead to the progressive loss 
of deformability and increased osmotic fragility of red blood cells (9). Consequently, diabetic 
patients with cardiovascular complications present with a decrease in haemoglobin (Hb) 
concentrations, mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin 
concentration (MCHC) which are haematological parameters for erythrocyte function (10). In 
addition. these changes induce the rapid initiation of apoptosis in damaged erythrocytes, 
decreasing the oxygen-carrying capacity of erythrocytes due to the increased haemolysis rate 
thereby significantly decreasing their lifespan (11). Apoptosis is characterised by membrane 
morphological alteration such as the exposure of the phosphatidylserine (PS) to the outer 
erythrocyte membrane surface which can be detected by staining with fluorescein 
isothiocyanate (FITC)-conjugated annexin-V, consequent membrane blebbing and 
microvesicle (MV) formation is observed (12). 
In addition, diabetic nephropathy arising from prolonged hyperglycaemia is associated with a 
decrease in erythropoietin (EPO) secretion which is the primary stimulus for erythropoiesis 
(13). Inadequate EPO secretion results in the decreased RBC production and thus diabetic 
anaemia (14). Insulin is currently the primary means of treatment for DM in addition to the 
hypoglycaemic and anti-hyperglycaemic drugs in the market (15). However, insulin has been 
shown to increase the rate of agglutination of erythrocyte, increasing the viscosity of blood and 
consequently increases arterial pressure, which augments cardiac myopathy particularly in high 
cardiovascular risk diabetic patients. Furthermore drugs such as metformin have been shown 
to contribute to the progression of anaemia through the malabsorption of vitamin B12 (16). 
Vitamin B12 is important for normal erythropoiesis and RBC maturation, from the digestive 
tract. There is therefore a need for economical, alternative treatment for DM patients who are 
at risk of developing cardiovascular complications (17). 
Various medicinal plants such as Momordica charantia and Syzygium cordatum (Hochst.) have 
been shown to possess anti-hyperglycaemic and reno-protective effects (18, 19). Hemidesmus 
indicus Linn has been shown to possess antioxidant activity and inhibited lipid peroxidation 
which may improve erythrocyte fragility and improve RBC function (20). Furthermore, 
medicinal plants such as Prosopis gradulosa have previously demonstrated the ability to 
increase haemoglobin concentrations (21). 
Of interest to our study is Momordica balsamina (MB), a plant widespread in Namibia, 
Botswana, Swaziland and all provinces of Southern Africa (22). In our laboratory, we have 
recently shown anti-hyperglycaemic and reno-protective effects of MB in STZ-induced 
diabetic rats. The reno-protective effects may have via its antioxidant properties, which may 
be of benefit to diabetic patients with hyperglycaemic-induced haematological changes. (23). 
Hence the need to evaluate the haematological effects of this plant which are not yet established 
(24). The aim of this study therefore, is to investigate the effects of Momordica balsamina on 
selected haematological parameters in experimental STZ-induced diabetic rats. 
 
 
 
55 
 
Materials and methods 
 
Drugs and chemicals 
 
Dimethyl sulphoxide (Sigma-Aldrich, St Louis, Missouri, United States of America); glucose 
(C6H12O6), metformin, monosodium citrate, calcium chloride (CaCl2), citric acid, (Merck 
chemicals (Pty) Ltd Wadeville, Johannesburg, South Africa); streptozotocin (Sigma Aldrich 
Chemical Company, Missouri, St Louis, USA); insulin (NovoRapid pen refill, Novordisk Pty 
Ltd, Sandton, South Africa); FITC annexin-V (clone 563), BD Falcon round-bottom tubes 
(BD Biosciences, San Jose, CA); phosphate buffered saline (PBS) ( Sigma Aldrich Co., St. 
Louis, MO).  
 
Plant extraction  
 
Professor H Baijnath, the former chief taxonomist/curator of the University of KwaZulu-Natal 
department of botany identified and authenticated Momordica balsamina leaves. The 
extraction of Momordica balsamina leaves were executed in the School of laboratory 
Medicine and Medical Sciences, at the University of KwaZulu-Natal, Westville Campus, 
following a previously validated protocol which has been previously reported by our 
laboratory (25). Briefly, the air-dried Momordica balsamina leaves (1.15kg) were sequentially 
extracted for 24 hours by cold percolation with methanol (95%, 6.9L). The methanolic extract 
was recovered from the mixture and methanol was added to the pulp for further extraction. To 
maximise the extraction process to increase the yield (609g), the process was repeated three 
times. The three extracts were combined to yield a concentrated methanolic extract at a 
reduced pressure (22-26mmHg) and temperature of 45-60 ºC. 
 
Animals 
 
In the present study, 30 male Sprague-Dawley rats (250-300 g) bred and housed in the 
Biomedical Research Unit (BRU) of University of KwaZulu-Natal. The rats were maintained 
under standard laboratory conditions of constant temperature (22±2 ºC), CO2 content of ˂ 5000 
p.m., relative humidity of 55±5% and illumination (12 h light/dark cycles) with the noise 
levels of less than 65 decibels. The animals were given standard rat chow daily and free access 
to water. Procedures performed on animal and their care were conducted in conformity with 
the institutional guidelines of the University of KwaZulu-Natal (AREC/023/017M). Before 
the study commenced, the animals were allowed to acclimatize for 5 days in metabolic cages. 
 
Induction of diabetes mellitus 
 
Type 1 diabetes mellitus were induced by a single intraperitoneal injection of 60 mg kg-1 STZ 
in freshly prepared 0.1 M citrate buffer (pH 4.5). Control group received the vehicle, citrate 
buffer via the same route. Animals that exhibited glucosuria after 24 h, when tested by urine 
strips were considered diabetic. Seven days following the induction of diabetes, the blood 
glucose concentration of STZ-induced diabetic animals above 20 mmol L-1 were regarded as 
stable diabetes. 
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Experimental design  
 
The short-term effects of Momordica balsamina methanolic (MB) extract and standard drugs 
(insulin and metformin) were monitored over 5 weeks for haematological parameters in 
separate groups of non-diabetic (group 1) and STZ-induced diabetic (group 2-5) male 
Sprague-Dawley (SD) rats. Rats were individually housed in Makrolon polycarbonate 
metabolic cages (Techniplast, Labotec, South Africa). Group 1 received the drug vehicle 
DMSO to serve as a negative control. Momordica balsamina methanolic extract (250 mg kg-
1, p.o.) were administered to Group 2. Group 3 and 4 served were treated with insulin (175 μg 
kg-1, s.c.) and metformin (500 mg kg-1, p.o.), respectively, serving as positive controls. Non-
diabetic animals in Group 5 served as absolute. MB was administered twice daily at 09h00 
and 15h00. Blood glucose concentrations were measured every 3rd day at 09:00 for the 
duration of experimental period via the tail pricking method using the Elite® glucometer (Elite 
(Pty) Ltd., Health Care Division, South Africa) assessed.). The weekly haematocrit was 
measured with a micro-haematocrit, with 75x 16 mm capillary tubes filled with blood also 
collected similarly and centrifuged for 5 min (Cheesbrough, 2004). The EDTA anti-
coagulated blood was collected into the capillary tubes, which were then sealed at one end 
with plasticine, and centrifuged at 3000g for 5 min, after which red cell levels in the capillary 
tubes were read using the microhaematocrit reader.  
 
Terminal studies 
 
At the end of the 5-week experimental period, all animals were sacrificed by exposing to 
halothane via a gas anaesthetic chamber (100 mg kg-1) for 3 minutes (Biomedical Resource 
Unit, UKZN, Durban, South Africa). Thereafter blood was collected by cardiac puncture 
(RBCP) into individual pre-cooled heparinized container and centrifuged (Eppendorf 
centrifuge 5403, Germany) at 4 °C, 503 g for 15 minutes and separated plasma was stored at 
-80 °C in a Bio Ultra freezer (Snijers Scientific, Holland) for hormonal analysis. In addition, 
the remaining RBCs were stored in separate Eppendorf tubes and stored at -80 °C in a Bio 
Ultra freezer until use for flow cytometry analysis. The kidneys were removed for biochemical 
analysis. 
 
Haematological analysis 
 
Whole blood was collected from groups of untreated and treated diabetic animals to measure 
red blood cell (RBC) count, Mean Cell Haemoglobin (MCH), mean cell heamoglobin 
concentration (MCHC) and mean cell volume (MCV) using an automated haematology 
analyser (Beckman Coulter, California, United States).  
 
Oxidative stress and erythropoietin analysis  
 
To establish the effects of treatment on oxidative stress, levels of MDA, a commonly known 
marker of lipid peroxidation, were measured in plasma and kidneys using a biochemical assay 
as described below compared (26).The antioxidant defence enzymes: Superoxide dismutase 
(SOD) and glutathione peroxide (GPx) in plasma and kidney tissues of experimental animals 
were also measured using ELISA kits. Erythropoietin (EPO) concentrations were also 
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measured in the plasma of experimental animals of untreated and treated animals using an 
ELISA kit.  
Malondialdehyde measurement 
 
Kidney tissues (50 mg) were homogenized. The homogenate was centrifuged at 400 x g for 
10 min. 500 µL of 0.2% phosphoric acid was added to the kidney homogenate and 100 µL 
plasma, respectively. Thereafter, 400 µL of both the homogenate and plasma were each 
supplemented with 400 µL 2% phosphoric acid and then separated into three glass tubes, each 
receiving equal volumes of the solution. Subsequently, 200 µL of 7% phosphoric acid was 
added into all glass tubes followed by the addition of 400 µL of thiobarbituric acid 
(TBA)/butylated hydroxytoluene (BHT) into two glass tube (sample tests) and 400 µL of 3 
mM hydrochloric acid (HCl) into the third glass tube (blank). To ensure an acidic pH of 1.5, 
200 µL of 1 M, HCl was added to sample and blank test tubes. All solutions were heated at 
100 ̊C for 15 min, and allowed to cool to room temperature. Butanol (1.5 mL) was added to 
the cooled solution; the sample was vortexed for 1 min to ensure rigorous mixing and allowed 
to settle until two phases are distinguished. The butanol phase (top layer) was transferred to 
Eppendorf tubes and centrifuged at 13,200 x g for 6 min. The samples were aliquoted into a 
96-well microtiter plate in triplicate and the absorbance was read at 532 nm (reference 600 
nm) on a BioTek µQuant spectrophotometer (Biotek, Johannesburg, South Africa). The 
absorbance from these wavelengths were used to calculate the concentration of MDA using 
Beer’s Law. 
 Concentration of MDA (mM)  
=
Average Absorbance
Absorption coefficient (156 mmo𝑙−1)
 
 
Superoxide dismutase and glutathione peroxidase and erythropoietin concentration 
 
SOD and GPx concentrations in plasma and kidney tissues, plasma EPO were analysed using 
a specific ELISA kit (Elabscience and Biotechnology, WuHan) that uses the Sandwich-ELISA 
method. Kits included micro ELISA plate which were coated with antibody specific to SOD, 
GPx and EPO. Standards and samples were pipetted into the appropriate wells of the micro 
ELISA plate and incubated for 90 minutes. The plate relevant biotinylated detection antibody 
(100 µL) was then added and incubated for 60 minutes. Avidin-Horseradish Peroxidase (HRP) 
conjugate (100 µL) was added to each micro-plate well and incubated for 30 minutes. 
Unbound components were washed out. Substrate solution (100 µL) was added to each micro-
plate well. After incubating for a further 15 minutes, the stop solution (50 µL) was added. The 
optical density was measured using a Nano spectrophotometer (BMG Labtech, Ortenburg, 
Baden-Wurttemberg, Germany) at the wavelength of 450 nm. The concentration of the 
samples was extrapolated from the respective standard curves. 
 
Flow cytometry 
 
A comparison of the percentage of red blood cells (RBC) expressing annexin-V among 
untreated and treated STZ-induced diabetic rats. 
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Red blood cell membrane analysis  
 
Instrument set up: BD FACS Canto-II flow cytometer and BD FACSdiva software (BD 
Biosciences, San Jose, CA) were used to acquire data. In order to report standardized results, 
BD cytometer setup and tracking beads (BD Biosciences, San Jose, CA) were used for flow 
check to verify the cytometer’s optical path and laminar flow. 
 Detector settings: This In order to detect small particles, forward scatter (FS) and side scatter 
(SS) parameters, were set at a log-scale (Figure 1 A). Voltages for the FS/SS photomultiplier 
tubes were set using an unstained fresh blood sample (Figure 1B). Antibody titration assays 
were then performed to detect optimal antibody concentrations.  
Measurement of apoptotic red blood cell levels: Annexin-V FITC was used (Figure 1 B) as 
this antibody binds to the translocated phosphatidylserine (PS) from the inner leaflet of the 
plasma membrane to the outer leaflet consequently exposing PS to the external environment. 
Briefly, 50 µL of heparinized RBCs were stained with annexin-V FITC (1:10) antibody and 
incubated in the dark for 20 minutes at room temperature; samples were then suspended in 
500 µL of PBS and analysed immediately.  
 
Figure 1: Gating strategy for annexin-V expression. The figure shows the gating strategy 
applied. (A) The colour dot plot depicts the red blood cells (RBCs) based on forward scatter 
(FSC) and side scatter (SS). (B) Demonstrates the expression of annexin-V. 
 
Statistical analysis 
 
All data are expressed as means ± standard error of means (SEM). To perform statistical 
analysis, GraphPad Prism Instat Software (version 5.00, GraphPad Software, San Diego, 
California, USA) was used. Blood glucose was analysed using analysis of variance (ANOVA) 
followed by Bonferroni post hoc test. ANOVA was used to analyse terminal parameters to 
analyse the differences between control and experimental groups. Values of p<0.05 were 
considered statistical significant between the compared groups. 
 
59 
 
Results 
 
Blood glucose concentration 
 
Figure 2 illustrates the blood glucose concentrations in non-diabetic control (NC), diabetic 
control (DC) and diabetic animals treated with Momordica balsamina (MB) (250 mg kg-1), 
metformin (MTF) and insulin (INS) over an experimental period of 5weeks. The untreated 
STZ-induced diabetic animals showed a significantly high blood glucose concentration 
throughout the period of 5 weeks by comparison with non-diabetic control α (DC vs NC, 
p<0.05, Figure 2). Treatment with MB, insulin and metformin showed a significant decrease 
in blood glucose concentration from week three to week five by comparison with the diabetic 
control *(MB vs DC, p<0.05, Figure 2). At week 5, blood glucose concentrations of animals 
treated with insulin significantly decreased by comparison with animals treated with MB λ 
(INS vs MB, p<0.05, Figure 2).  
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Figure 2: Blood glucose concentration in non-diabetic control (NC), diabetic control (DC) and 
diabetic animals treated with Momordica balsamina (MB), metformin (MTF) and insulin (INS) 
over the period of 5 weeks. Values are presented as means and vertical bars indicate SEM (n=6 
in each group). α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by 
comparison with diabetic control. λ p˂0.05 by comparison with MB treated animals. 
 
Haematological parameters 
 
Table 1 shows the comparisons of haematological parameters in non-diabetic control (NC), 
diabetic control (DC) and STZ-induced diabetic animals treated with Momordica balsamina 
(MB) (250 mg kg-1), metformin (MTF) and insulin (INS) at the end of the 5 weeks of treatment. 
Haematocrit and haemoglobin in untreated STZ-diabetic rats was significantly decreased in 
comparison to untreated non-diabetic rats. RBC in untreated STZ-diabetic rats were 
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significantly lower than untreated non-diabetic rats α (DC vs NC, p<0.05). Interestingly, MB 
significantly increased the haematocrit, RBC and haemoglobin similarly to insulin and 
metformin treated rats by comparison with untreated STZ-diabetic rats *(MB vs DC, p<0.05). 
Red blood cell indices including MCV, MCHC, MCH in untreated animals slightly decreased 
by comparison non-diabetic animal. In addition, MB, insulin and metformin treatment 
moderately improved RBC indices in by comparison to untreated animals although no 
significance was reached. 
 
Table 1: Shows the comparison of haematological parameters in non-diabetic control (NC), 
diabetic control (DC) and STZ-induced diabetic animals treated with Momordica balsamina 
(MB) (250 mg kg-1), metformin (MTF) and insulin (INS). Values are presented as means ±SEM 
(n=6 per group). 
 
Treatment 
Parameters 
measured  
NC DC INS MTF MB 
RBC 
(×106cells/µL) 
06.66 ± 0.41 05.39 ± 0.06 α 08.60 ± 0.31 * 08.56 ± 0.09 * 07.31 ± 0.44 * 
Hct 
(%) 
38.58 ± 0.05 31.38 ± 0.57 α 43.41 ± 2.34 * 44.15 ± 1.59 * 45.93 ± 0.43 * 
Hb 
(g/dL) 
13.07 ± 0.61 09.16 ± 0.18 α 15.23 ± 0.81 * 16.05 ± 0.47 * 15.82 ± 0.22 * 
MCHC 
(g/dL) 
37.18 ± 0.63 36.10 ± 0.20 35.60 ± 0.58 34.87 ± 0.81 36.15 ± 0.80 
MCV 
(fL/cell) 
51.83 ± 0.75 50.66 ± 0.21 52.83 ± 0.47 53.00 ± 0.58 51.33 ± 1.05 
MCH 
(pg/cell) 
19.21 ± 0.52 17.00 ± 0.29 19.33 ± 0.59 19.45 ± 0.67 18.98 ± 0.16 
α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by comparison with 
diabetic control. 
 
MDA, SOD and GPx concentrations 
 
Table 2 shows the comparisons of MDA, SOD and GPx concentrations in both plasma and 
kidney tissues in non-diabetic control (NC), diabetic control (DC) and diabetic animals treated 
with Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS) at the 
end of the 5 weeks of treatment. Plasma and kidney tissues of untreated STZ-diabetic animals 
presented with increased concentrations in MDA by comparison to untreated non-diabetic rats 
α (DC vs NC, p<0.05). Furthermore, there was a significant decrease in both plasma and kidney 
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SOD and GPx concentrations in untreated STZ-diabetic animals, respectively, by comparison 
with untreated non-diabetic animals α (DC vs NC, p<0.05). Both plasma and kidney tissues of 
MB treated STZ-induced diabetic rats, similarly to insulin and metformin treated rats, 
presented with a significant decrease in MDA concentrations by comparison to both plasma 
and kidney tissues in untreated diabetic rats *(MB vs DC, p<0.05). In addition, plasma and 
kidney GPx concentrations improved while plasma SOD concentrations deteriorated by 
comparison to untreated STZ-induced diabetic rats *(MB vs DC, p<0.05).  
 
Table 2: Comparison of MDA, SOD and GPx concentrations of both the plasma and kidney 
tissues in non-diabetic control (NC), diabetic control (DC) and diabetic animals treated with 
Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS). Values are 
presented as means ±SEM (n=6). 
 
                              Plasma           Kidney   
MDA (μmol/g protein) NC 0.68 ± 0.12 0.99 ± 0.02 
DC 9.37 ± 1.19 α 4.21 ± 0.12 α 
INS 0.54 ± 0.03 * 1.10 ± 0.01 * 
MTF 0.35 ± 0.06 * 1.19 ± 0.01 * 
MB 2.48 ± 0.05 * 1.14 ± 0.01 * 
  
GPx Concentration (ng/mL) NC 1.44 ± 0.03 2137.31   ± 0.03 
DC 0.21 ± 0.04 α 1703.491 ± 0.03 α 
INS 0.83 ± 0.01 * 2062.21   ± 0.02 * 
MTF 1.67 ± 0.01 * 2125.75   ± 0.01 * 
MB 1.06 ± 0.04 * 21370.37 ± 0.03 * 
  
SOD Concentration (ng/mL) 
 
NC 35.39 ± 0.63 13.43 ± 0.76 
DC 33.55 ± 0.27 06.01 ± 0.09 α 
INS 31.68 ± 2.76 09.89 ± 0.10 * 
MTF 29.85 ± 2.44 10.11 ± 0.02 * 
MB 23.63 ± 0.87 * 10.08 ± 0.05 * 
α p˂0.05 by comparison with non-diabetic control animals. * p˂0.05 by comparison with 
diabetic control. 
Plasma erythropoietin concentrations 
 
Figure 3 visualises the comparisons of plasma erythropoietin (EPO) concentration in non-
diabetic control (NC), diabetic control (DC) and diabetic animals treated with Momordica 
balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS) after 5 weeks of the 
experimental period. Diabetic controls showed a significant decrease in plasma EPO 
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concentration by comparison to the non-diabetic control group α (DC vs NC, p<0.05, Figure 
3). Interestingly, the administration of MB, similarly to insulin, and metformin significantly 
increased plasma erythropoietin concentrations after the 5-week experimental period *(MB vs 
DC, p<0.05, Figure 3). 
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Figure 3: Plasma erythropoietin concentration in non-diabetic control (NC), diabetic control 
(DC) and diabetic animals treated with Momordica balsamina (MB), metformin (MTF) and 
insulin (INS) after the period of 5 weeks. Values are presented as means and vertical bars 
indicate SEM (n=6 in each group). α p˂0.05 by comparison with non-diabetic control animals. 
* p˂0.05 by comparison with diabetic control. 
 
Percentage of annexin-V on red blood cell membrane  
 
Figure 4 visualizes the comparisons percentage of annexin-V expressed on red blood cell 
membrane in non-diabetic control (NC), diabetic control (DC) and diabetic animals treated 
with Momordica balsamina (MB) (250 mg kg-1), metformin (MTF) and insulin (INS) measured 
upon termination of the 5-week experimental period. Diabetic controls a significantly increased 
red blood cell annexin-V expression by comparison to the non-diabetic control group α (DC vs 
NC, p<0.05, Figure 4). Insulin and metformin treated animals exhibited a significant decrease 
in the percentage of annexin-V expressed on red blood cell membrane by comparison with 
untreated STZ-induced diabetic animals *(INS vs DC, p<0.05, Figure 4),*(MTF vs DC, 
p<0.05, Figure 4). However, the administration of MB increased the percentage of annexin-V 
expressed on red blood cell membrane significantly by comparison to both untreated STZ-
induced diabetic animals after the 5-week experimental period *(MB vs DC, p<0.05, Figure 
4). 
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Figure 4: The percentage of red blood cell membranes expressing annexin-V in non-diabetic 
control (NC), diabetic control (DC) and diabetic animals treated with Momordica balsamina 
(MB), metformin (MTF) and insulin (INS) after the experimental period of 5 weeks. Values 
are presented as means and vertical bars indicate SEM (n=6 in each group). α p˂0.05 by 
comparison with non-diabetic control animals. * p˂0.05 by comparison with diabetic control. 
 
Discussion 
 
Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycaemia which is 
associated with haematological changes that progress cardiovascular pathology (27, 28). The 
current study assessed the effects of treatment with Momordica balsamina methanolic extract 
on selected haematological parameters which have been shown to be altered under diabetic 
conditions, increasing cardiovascular dysfunction (29). In our laboratory, we have shown 
Momordica balsamina possesses anti-hyperglycaemic effects and ameliorates kidney 
dysfunction (23).  
The red blood cells (RBC) are adapted to readily undergo cellular deformation without 
rupturing as it navigates through the vascular system for gaseous exchange between blood and 
tissues (30). Furthermore, hyperglycaemia has been shown to impair erythrocyte deformability 
through increasing lipid peroxidation and oxidative stress, which increases their risk of 
rupturing which may account for the decrease in red blood cell count in the STZ-induced 
diabetic animals. The decrease in the number of RBCs was accompanied by a significant 
decline in haemoglobin (Hb) among the STZ-induced diabetic animals (31). The severe 
deterioration in Hb observed in the STZ diabetic animals suggest that the animals were anaemic 
since the decline was well below that of normal expected hemoglobin range (32). The Hb 
molecule contains iron atoms which bind oxygen atoms to be transported throughout the system 
(33). The increased risk of ischemia would consequently correlate with the development of 
cardiac myopathy in STZ-induced diabetic animals (34). In addition, as hyperglcaemia 
increases the glycation rate of Hb, thereby raising extracorpuscular Hb that has been shown to 
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decrease RBC fragility thus shortening the life span of RBCs. However, treatment with insulin, 
metformin and MB improved Hb concentrations to within a normal expected range, possibly 
via an improvement of hyperglycaemic state which was also observed by Komolafe and et al. 
when treating STZ-induced diabetic rats with Momordica charantia (35). Notably, the 
homeostatic shift of a decline in Hb concentrations had no statistical significant impact on RBC 
indices such as MCV, MCH and MCHC. However, there was a physiological significance as 
RBCs can present with normal mean corpuscular volume, a condition known as normocytic 
anaemia which may be associated with kidney dysfunction (36). In harmony with a study 
conducted by Keskin and et al. , MCV, MCH and MCHC of untreated STZ-induced diabetic 
rats, showed no significant change at the end of the experimental period (37). It has also been 
extensively shown in literature that STZ-induced diabetic animals have an increase in mean 
arterial blood pressure, which may further increase the rupturing rate of erythrocytes (38). 
However, the antidiabetic properties of Momordica balsamina may have buffered the MDA 
concentrations, attenuating lipid peroxidation as the RBC membrane is rich in lipids to 
maintain its fluidity to facilitate deformability without rupturing which was in agreement with 
previous studies (39). In addition, antioxidant status was improved through increasing GPx, 
which detoxifies ROS product, hydrogen peroxide, to water thereby partially restoring 
membrane integrity (5, 40). However, hyperglycaemia results in disturbances in protein 
function due increased production of ROS and non-enzymatic glycation of many proteins 
including superoxide dismutase rendering it inefficient as observed in our experimental 
animals. A plant with antidiabetic properties such as Allium sativum has been shown to inhibit 
alanine production in ROS exposed erythrocytes thereby protecting erythrocytes from protein 
degradation, loss of deformability and increased osmotic fragility (8). Surprisingly, 
administration with Momordica balsamina did not improve the exposure of phosphatidylserine 
(PS) to the extracellular fluid, which may mark the erythrocytes for engulfment by local 
macrophages. A study conducted by Parminder K, et al showed that the seeds of Momordica 
balsamina are rich in balsamin, which is a 28 kDa protein that has been shown to promote 
apoptosis in breast cancer cells (41). The increase in the apoptotic activity of Momordica 
balsamina treated animals may be therefore attributed to some proapoptotic properties of this 
plant. Further studies on other antidiabetic compounds of Momordica balsamina, such as 
flavonoids warrant investigation to further understand the mechanism by which medicinal 
plants may restore RBC membrane integrity in STZ-induced diabetic rats. In addition, due to 
ethical constraints, the experimental period was five weeks; therefore increasing the treatment 
period may have shown an improvement on some haematological function markers. 
The administration of STZ to mimic a type-1 diabetes rodent model has been shown to induce 
renal dysfunction which was previously observed in our laboratory (23). In addition, kidneys 
of STZ-induced diabetic rats in our study showed a decrease in the antioxidant status, which 
was associated with an insufficient erythropoietin secretion and RBC function. However, 
Momordica balsamina improved EPO secretion by the kidneys possibly through preventing 
the metabolic injury to peritubular interstitial fibroblast-like cells by advanced glycation end 
products (AGEs) formation. The increase in EPO, may account for the increase in RBC count 
and improvement in RBC indices in Momordica balsamina treated animals. Improving RBC 
function also restores the blood’s oxygen-carrying capacity, which may improve 
cardiovascular dysfunction associated with diabetes. 
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Conclusion 
 
As the foregoing discussion on the use of medicinal plants and their potential therapeutic 
effects on hyperglycaemia-induced haematological changes is underway, the current study 
enlightens some beneficial properties of Momordica balsamina administration. Results show 
improvement of the antioxidant status stemming from Momordica balsaminaa’s antidiabetic 
properties. This was associated with an improvement in RBC function possibly through 
increased EPO secretion although RBC membrane exposure of PS to the surface was not 
improved. Taken together, Momordica balsamina methanolic extract administration improves 
some haematological alterations associated with hyperglycaemia. Further investigations are 
envisaged to expand the indigenous knowledge in an effort to widen the spectrum range of 
easily accessible remedies for diabetes management. 
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Chapter 4: Synthesis 
 
Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycaemia which has 
been associated with micro and macroangiopathies that contribute to the increased mortility 
and morbidity rate of diabetic patients (1). Chronic hyperglycaemia increases the risk of 
developing cardiovascular complications and induces haematological changes that may 
aggravate cardiac dysfunction (2). In this study, we investigated the short-term effects of 
Momordica balsamina (MB) methanolic extract administration on selected cardiovascular and 
haematological function markers in streptozotocin (STZ)-induced diabetic rats. 
The induction of diabetes mellitus with STZ, an antibiotic that selectively destroys pancreatic 
β-cells, achieved a hyperglycaemic rat model as evidenced by the sustained hyperglycaemia of 
untreated animals. Studies have shown haematological and cardiovascular dysfunction in STZ-
induced hyperglycaemic animal models. In addition, literature has shown a link between 
alleviating hyperglycaemia-induced haematological changes and improved cardiac 
myopathies. Medicinal plants have shown the ability to lower blood glucose and improve 
haematological and cardiovascular function although the mechanisms have not been fully 
established. In particular, the effects of these medicinal plants on RBC structure and function.  
Hence, the study investigated the effects of Momordica balsamina methanolic extract on 
haematological and cardiovascular function of STZ-induced diabetic rats. In this present study, 
the selective destruction of pancreatic β cell resulted in insufficient insulin secretion thereby 
resulting in sustained hyperglycaemia in untreated animals. Furthermore, there was a 
deterioration of cardiac function as observed by an increase in proinflammatory cytokines such 
as carditrophin-I and C-reactive protein. The deterioration of cardiac function may have been 
associated with the elevated oxidative stress as marked by an increase in malondialdehyde 
(MDA) of untreated STZ-induced diabetic animals in this study. The increased oxidative stress 
was also associated with endothelial dysfunction as evidenced by an increase in a 
vasoconstrictor Ang-II. Furthermore, the cardiac dysfunction may have also been due to 
hyperglycaemia-induced haematological changes via increased lipid peroxidation as shown by 
increased MDA concentrations, which have been shown to decrease RBC function as marked 
by decreased MCV, MCH and MCHC observed in untreated diabetic animals. Furthermore, an 
alteration in RBC indices shows a compromised red blood cell profile that was further shown 
by a decline in haemoglobin concentrations, may progress to anaemia if left untreated. 
Haemoglobin is a protein which binds oxygen in RBCs for transport to cells, therefore 
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assessing haemoglobin may enlighten researchers on drug-target for the management of DM 
related haematological complications (178). An improvement in hyperglycaemia, oxidative 
stress upon treatment with MB was observed, suggesting that MB may possess bioactive 
compounds, which improve the antioxidant status and promote RBC production thus 
improving both haematological and cardiac function in diabetic animals. Since there was an 
improvement in the RBC production, we further assessed the quality of the RBCs by 
investigating the integrity of the RBC membrane. The integrity of the membrane of RBCs must 
be maintained in order for it to deform with ease through the vasculature without rupturing. 
However, when the RBC membrane is compromised as marked by the exposure of 
phosphatidylserine (PS) to the exterior, it is marked for engulfment by macrophages. The 
administration of Momordica balsamina therefore improved some cardiovascular and 
haematological parameters.  
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Conclusion 
Our results taken together show that the administration of Momordica balsamina methanolic 
extract has the potential to alleviate the haematological changes induced by hyperglycaemia by 
attenuating hyperglycaemia, oxidative stress and promoting erythropoietin secretion thus 
improving red blood cell profile. Furthermore, Momordica balsamina methanolic extract also 
improved cardiac function as observed by a decrease in mean arterial pressure, inflammation 
and cardiac hypertrophy. The ability of medicinal plants such as Momordica balsamina to 
improve red blood cell function may therefore be a therapeutic target for alleviating 
cardiovascular dysfunction often observed in diabetic patients.  
 
Recommendations 
Further studies on the isolation of the bioactive compounds of Momordica balsamina need to 
beconducted in order to further understand the mechanisms by which this plant improves 
haematological and cardiac function. Furthermore, studying the effects of bioactive compounds 
on other haematological parameters such as profiling red blood cell development in the bone 
marrow, white blood cell activation and platelet regulation, which are impaired in 
hypergylcaemia-induced cardiovascular complications, of treated experimental animals will 
further unveil the mechanisms by which medicinal plants may improve cardiac function. 
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or convert the images to one of the following formats (note the resolution requirements for line 
drawings, halftones, and line/halftone combinations given below): 
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'. 
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. 
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi. 
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 
dpi is required. 
Please do not: 
Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is 
too low. 
Supply files that are too low in resolution. 
Submit graphics that are disproportionately large for the content. 
Color artwork 
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) 
or MS Office files) and with the correct resolution. If, together with your accepted article, you 
submit usable color figures then Elsevier will ensure, at no additional charge, that these figures 
will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction 
in print. Further information on the preparation of electronic artwork. 
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Figure captions 
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the 
figure itself) and a description of the illustration. Keep text in the illustrations themselves to a 
minimum but explain all symbols and abbreviations used. 
Tables 
Please submit tables as editable text and not as images. Tables can be placed either next to the 
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in 
accordance with their appearance in the text and place any table notes below the table body. 
Be sparing in the use of tables and ensure that the data presented in them do not duplicate 
results described elsewhere in the article. Please avoid using vertical rules and shading in table 
cells. 
References 
Citation in text 
Please ensure that every reference cited in the text is also present in the reference list (and vice 
versa). Any references cited in the abstract must be given in full. Unpublished results and 
personal communications are not recommended in the reference list, but may be mentioned in 
the text. If these references are included in the reference list they should follow the standard 
reference style of the journal and should include a substitution of the publication date with 
either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' 
implies that the item has been accepted for publication. 
Reference links 
Increased discoverability of research and high quality peer review are ensured by online links 
to the sources cited. In order to allow us to create links to abstracting and indexing services, 
such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are 
correct. Please note that incorrect surnames, journal/book titles, publication year and 
pagination may prevent link creation. When copying references, please be careful as they may 
already contain errors. Use of the DOI is highly encouraged. 
A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic 
article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., 
Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser 
Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, 
https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in 
the same style as all other references in the paper. 
Web references 
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As a minimum, the full URL should be given and the date when the reference was last accessed. 
Any further information, if known (DOI, author names, dates, reference to a source publication, 
etc.), should also be given. Web references can be listed separately (e.g., after the reference 
list) under a different heading if desired, or can be included in the reference list. 
Data references 
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing 
them in your text and including a data reference in your Reference List. Data references should 
include the following elements: author name(s), dataset title, data repository, version (where 
available), year, and global persistent identifier. Add [dataset] immediately before the reference 
so we can properly identify it as a data reference. The [dataset] identifier will not appear in 
your published article. 
References in a special issue 
Please ensure that the words 'this issue' are added to any references in the list (and any citations 
in the text) to other articles in the same Special Issue. 
Reference management software 
Most Elsevier journals have their reference template available in many of the most popular 
reference management software products. These include all products that support Citation Style 
Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor 
plug-ins from these products, authors only need to select the appropriate journal template when 
preparing their article, after which citations and bibliographies will be automatically formatted 
in the journal's style. If no template is yet available for this journal, please follow the format of 
the sample references and citations as shown in this Guide. If you use reference management 
software, please ensure that you remove all field codes before submitting the electronic 
manuscript. More information on how to remove field codes. 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the 
following link: 
http://open.mendeley.com/use-citation-style/chemico-biological-interactions 
When preparing your manuscript, you will then be able to select this style using the Mendeley 
plugins for Microsoft Word or LibreOffice. 
Reference formatting 
There are no strict requirements on reference formatting at submission. References can be in 
any style or format as long as the style is consistent. Where applicable, author(s) name(s), 
journal title/book title, chapter title/article title, year of publication, volume and issue/book 
chapter and the pagination must be present. Use of DOI is highly encouraged. The reference 
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style used by the journal will be applied to the accepted article by Elsevier at the proof stage. 
Note that missing data will be highlighted at proof stage for the author to correct. If you do 
wish to format the references yourself they should be arranged according to the following 
examples: 
Reference style 
Text: Indicate references by number(s) in square brackets in line with the text. The actual 
authors can be referred to, but the reference number(s) must always be given. 
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....' List: 
Number the references (numbers in square brackets) in the list in the order in which they appear 
in the text. 
Examples: 
Reference to a journal publication: 
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. 
Commun. 
163 (2010) 51–59. https://doi.org/10.1016/j.Sc.2010.00372. 
Reference to a journal publication with an article number: 
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. 
Heliyon. 
19, e00205. https://doi.org/10.1016/j.heliyon.2018.e00205. 
Reference to a book: 
W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000. 
Reference to a chapter in an edited book: 
G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, 
R.Z.Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 
281–304. 
Reference to a website: 
Cancer Research UK, Cancer statistics reports for the UK. 
http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13 
March 2003). 
Reference to a dataset: 
[dataset] [6] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak 
wilt disease and surrounding forest compositions, Mendeley Data, v1, 2015. 
https://doi.org/10.17632/ xwj98nb39r.1. 
Journal abbreviations source 
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Journal names should be abbreviated according to the List of Title Word Abbreviations. 
Video 
Elsevier accepts video material and animation sequences to support and enhance your scientific 
research. Authors who have video or animation files that they wish to submit with their article 
are strongly encouraged to include links to these within the body of the article. This can be 
done in the same way as a figure or table by referring to the video or animation content and 
noting in the body text where it should be placed. All submitted files should be properly labeled 
so that they directly relate to the video file's content. . In order to ensure that your video or 
animation material is directly usable, please provide the file in one of our recommended file 
formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation 
files supplied will be published online in the electronic version of your article in Elsevier Web 
products, including ScienceDirect. Please supply 'stills' with your files: you can choose any 
frame from the video or animation or make a separate image. These will be used instead of 
standard icons and will personalize the link to your video data. For more detailed instructions 
please visit our video instruction pages. Note: since video and animation cannot be embedded 
in the print version of the journal, please provide text for both the electronic and the print 
version for the portions of the article that refer to this content. 
Data visualization 
Include interactive data visualizations in your publication and let your readers interact and 
engage more closely with your research. Follow the instructions here to find out about available 
data visualization options and how to include them with your article. 
Supplementary material 
Supplementary material such as applications, images and sound clips, can be published with 
your article to enhance it. Submitted supplementary items are published exactly as they are 
received (Excel or PowerPoint files will appear as such online). Please submit your material 
together with the article and supply a concise, descriptive caption for each supplementary file. 
If you wish to make changes to supplementary material during any stage of the process, please 
make sure to provide an updated file. Do not annotate any corrections on a previous version. 
Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in 
the published version. 
Research data 
This journal encourages and enables you to share data that supports your research publication 
where appropriate, and enables you to interlink the data with your published articles. Research 
data refers to the results of observations or experimentation that validate research findings. To 
90 
 
facilitate reproducibility and data reuse, this journal also encourages you to share your 
software, code, models, algorithms, protocols, methods and other useful materials related to 
the project. 
Below are a number of ways in which you can associate data with your article or make a 
statement about the availability of your data when submitting your manuscript. If you are 
sharing data in one of these ways, you are encouraged to cite the data in your manuscript and 
reference list. Please refer to the "References" section for more information about data citation. 
For more information on depositing, sharing and using research data and other relevant 
research materials, visit the research data page. 
Data linking 
If you have made your research data available in a data repository, you can link your article 
directly to the dataset. Elsevier collaborates with a number of repositories to link articles on 
ScienceDirect with relevant repositories, giving readers access to underlying data that gives 
them a better understanding of the research described. 
There are different ways to link your datasets to your article. When available, you can directly 
link your dataset to your article by providing the relevant information in the submission system. 
For more information, visit the database linking page. 
For supported data repositories a repository banner will automatically appear next to your 
published article on ScienceDirect. 
In addition, you can link to relevant data or entities through identifiers within the text of your 
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 
734053; PDB: 1XFN). 
Mendeley Data 
This journal supports Mendeley Data, enabling you to deposit any research data (including raw 
and processed data, video, code, software, algorithms, protocols, and methods) associated with 
your manuscript in a free-to-use, open access repository. During the submission process, after 
uploading your manuscript, you will have the opportunity to upload your relevant datasets 
directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to 
your published article online. 
For more information, visit the Mendeley Data for journals page. 
Data in Brief 
You have the option of converting any or all parts of your supplementary or additional raw data 
into one or multiple data articles, a new kind of article that houses and describes your data. 
Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a 
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DOI and publicly available to all upon publication. You are encouraged to submit your article 
for Data in Brief as an additional item directly alongside the revised version of your 
manuscript. If your research article is accepted, your data article will automatically be 
transferred over to Data in Brief where it will be editorially reviewed and published in the open 
access data journal, Data in Brief. Please note an open access fee of 500 USD is payable for 
publication in Data in Brief. Full details can be found on the Data in Brief website. Please use 
this template to write your Data in Brief. 
MethodsX 
You have the option of converting relevant protocols and methods into one or multiple 
MethodsX articles, a new kind of article that describes the details of customized research 
methods. Many researchers spend a significant amount of time on developing methods to fit 
their specific needs or setting, but often without getting credit for this part of their work. 
MethodsX, an open access journal, now publishes this information in order to make it 
searchable, peer reviewed, citable and reproducible. Authors are encouraged to submit their 
MethodsX article as an additional item directly alongside the revised version of their 
manuscript. If your research article is accepted, your methods article will automatically be 
transferred over to MethodsX where it will be editorially reviewed. Please note an open access 
fee is payable for publication in MethodsX. Full details can be found on the MethodsX website. 
Please use this template to prepare your MethodsX article. 
Data statement 
To foster transparency, we encourage you to state the availability of your data in your 
submission. This may be a requirement of your funding body or institution. If your data is 
unavailable to access or unsuitable to post, you will have the opportunity to indicate why during 
the submission process, for example by stating that the research data is confidential. The 
statement will appear with your published article on ScienceDirect. For more information, visit 
the Data Statement page. 
Additional information 
It is understood that with submission of this article the authors have complied with the 
institutional policies governing the humane and ethical treatment of the experimental subjects, 
and that they are willing to share the original data and materials if so requested. 
AFTER ACCEPTANCE 
Online proof correction 
Corresponding authors will receive an e-mail with a link to our online proofing system, 
allowing annotation and correction of proofs online. The environment is similar to MS Word: 
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in addition to editing text, you can also comment on figures/tables and answer questions from 
the Copy Editor. Web-based proofing provides a faster and less error-prone process by 
allowing you to directly type your corrections, eliminating the potential introduction of errors. 
If preferred, you can still choose to annotate and upload your edits on the PDF version. All 
instructions for proofing will be given in the e-mail we send to authors, including alternative 
methods to the online version and PDF. 
We will do everything possible to get your article published quickly and accurately. Please use 
this proof only for checking the typesetting, editing, completeness and correctness of the text, 
tables and figures. Significant changes to the article as accepted for publication will only be 
considered at this stage with permission from the Editor. It is important to ensure that all 
corrections are sent back to us in one communication. Please check carefully before replying, 
as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your 
responsibility. 
Offprints 
The corresponding author will, at no cost, receive a customized Share Link providing 50 days 
free access to the final published version of the article on ScienceDirect. The Share Link can 
be used for sharing the article via any communication channel, including email and social 
media. For an extra charge, paper offprints can be ordered via the offprint order form which is 
sent once the article is accepted for publication. Both corresponding and co-authors may order 
offprints at any time via Elsevier's Webshop. Corresponding authors who have published their 
article gold open access do not receive a Share Link as their final published version of the 
article is available open access on ScienceDirect and can be shared through the article DOI 
link. 
AUTHOR INQUIRIES 
Visit the Elsevier Support Center to find the answers you need. Here you will find everything 
from Frequently Asked Questions to ways to get in touch. 
You can also check the status of your submitted article or find out when your accepted article 
will be published. 
© Copyright 2018 Elsevier | https://www.elsevier.com 
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Appendix 3 – Manuscript 2 Journal guide  
 
Journal Title 
Concise and Informative Article Title 
Firstname M. I. Lastname,1 Firstname A. Lastname,2 and Firstname B. Lastname1,2 
1 Department, Institute, City ZIP/Post code, Country. 
2 Department, Institute, City ZIP/Post code, Country. 
Correspondence should be addressed to Firstname B. Lastname; lastname@institution.edu 
Abstract 
The abstract should be a single, self-contained paragraph which summarises the manuscript. 
Ideally, it will provide a brief context for the study, before describing the scientific approach 
and some key results in a qualitative manner. It should finish with a sentence to describe the 
implications for the field. The abstract must not include references, figures or tables. 
Introduction 
The introduction should be succinct, with no subheadings. Limited figures may be included 
only if they are truly introductory, and contain no new results. 
Materials and Methods 
The materials and methods section should contain sufficient detail so that all procedures can 
be repeated. It may be divided into headed subsections if several methods are described. 
Results and Discussion 
Subheadings 
The results and discussion may be presented separately, or in one combined section, and may 
optionally be divided into headed subsections.  
Advice on Equations 
Equations should be provided in a text format, rather than as an image. Microsoft Word’s 
equation tool is acceptable. Equations should be numbered consecutively, in round brackets, 
on the right-hand side of the page. They should be referred to as Equation 1, etc. in the main 
text. 
𝑥 =
−𝑏±√𝑏2−4𝑎𝑐
2𝑎
     (1) 
Advice on Figures 
At the point of submission, authors may provide all figures embedded within the manuscript 
at a convenient break near to where they are first referenced or, alternatively, they may be 
provided as separate files. All figures should be cited in the paper in a consecutive order. 
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Where possible, figures should be displayed on a white background. When preparing figures, 
consider that they can occupy either a single column (half page width) or two columns (full 
page width), and should be sized accordingly. All figures must have an accompanying 
caption which includes a title and, preferably, a brief description (see Figure 1). 
 
Figure 1: Basic rocket ship design. The rocket ship is propelled with three thrusters and 
features a single viewing window. The nose cone is detachable upon impact. 
The caption can also be used to explain any acronyms used in the figure, as well as providing 
information on scale bar sizes or other information that cannot be included in the figure itself. 
Plots that show error bars should include in the caption a description of how the error was 
calculated and the sample size (see Figure 2). 
 
Figure 2: Plot of nanoparticle size with respect to time, recorded over a 90 s period. The error 
bars represent the standard deviation of measurements for 20 particles in five separate sample 
runs (n = 100). 
If a figure consists of multiple panels, they should be ordered logically and labelled with 
lower case roman letters (i.e., a, b, c, etc.). If it is necessary to mark individual features within 
a panel (e.g., in Figure 3a), this may be done with lowercase Roman numerals, i, ii, iii, iv, etc. 
All labels should be explained in the caption. Panels should not be contained within boxes 
unless strictly necessary. 
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Figure 3: Representations of some common weather symbols. (a) The sun with (i) core, and 
(ii) rays. (b) Thunder bolt. (c) Cloud. (d) Moon. 
Upon acceptance, authors will be asked to provide the figures as separate electronic files. At 
that stage, figures should be supplied in either vector art formats (Illustrator, EPS, WMF, 
FreeHand, CorelDraw, PowerPoint, Excel, etc.) or bitmap formats (Photoshop, TIFF, GIF, 
JPEG, etc.). Bitmap images should be of at least 300 dpi resolution, unless due to the limited 
resolution of a scientific instrument. If a bitmap image has labels, the image and labels should 
be embedded in separate layers. 
Advice on Tables 
Every table must have a descriptive title and, if numerical measurements are given, the units 
should be included in the column heading. Vertical rules should not be used (see Table 1). 
Tables should be cited consecutively in the text. 
Table 1: Temperature and wildlife count in the three areas covered by the study. 
Location T [° C] Turtles Sharks Octopuses Starfish 
Blue Lagoon 21.2 5 3 4 543 
Regent’s Canal 5.2 8 0 24 312 
Shark Bay 12.8 4 7 9 122 
Conclusions 
The Conclusions section should clearly explain the main findings and implications of the 
work, highlighting its importance and relevance. 
Data Availability 
A data availability statement is compulsory for research articles and clinical trials. Here, 
authors must describe how readers can access the data underlying the findings of the study, 
giving links to online repositories and providing deposition codes where applicable. For more 
information on how to compose a data availability statement, including template examples, 
please visit: https://www.hindawi.com/research.data/#statement. 
Conflicts of Interest 
This section is compulsory. A competing interest exists when professional judgment 
concerning the validity of research is influenced by a secondary interest, such as financial 
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gain. We require that our authors reveal any possible conflict of interest in their submitted 
manuscripts. If there is no conflict of interest, authors should state that “The author(s) 
declare(s) that there is no conflict of interest regarding the publication of this paper.” 
 
Some of the information you choose to provide here may constitute your “sensitive personal 
data”. Please read our Privacy Policy for further information on how we handle your personal 
data. 
Funding Statement 
Authors should state how the research and publication of their article was funded, by naming 
financially supporting bodies followed by any associated grant numbers in square brackets. 
Acknowledgments 
An Acknowledgements section is optional and may recognise those individuals who provided 
help during the research and preparation of the manuscript. 
Supplementary Materials 
If Supplementary Materials are provided (e.g., audio files, video clips or datasets) they should 
be described here. Note that authors are responsible for providing the final Supplementary 
Materials files that will be published along with the article, which are not modified by our 
production team. You should remember to reference the Supplementary Materials’ contents 
at appropriate points within the manuscript. We recommend citing specific items, rather than 
referring to the Supplementary Materials in general, for example: “See Figures S1-S10 in the 
Supplementary Material for comprehensive image analysis.” 
References 
References will be reformatted in house, there is no need to adhere to a specific style at the 
point of submission. Authors are responsible for ensuring that the information in each 
reference is complete and accurate. All citations in the text must be numbered consecutively 
in square brackets, before any punctuation, for example, “as discussed by Smith [1],” and “as 
discussed elsewhere [2,3].” All uncited references will be automatically removed. The 
references should not contain footnotes. For your information, our citation style is: 
[x] Author initials and surname, “Title in sentence style,” Journal title, vol. (volume 
number), no. (issue number), pp. (page numbers separated by an en-dash), Year. 
For example: 
[1] J. D. Watson and F. H. C. Crick, “A structure for deoxyribose nucleic acid,” Nature, 
vol. 171, no. 4356, pp. 737–738, 1953. 
97 
 
For articles with six or more authors, the first three authors are listed followed by ‘et al.’. 
When journals use only article numbers, no page numbers are necessary. For example: 
[2] B. P. Abbott, R. Abbott, T. D. Abbott et al., “Observation of Gravitational Waves 
from a Binary Black Hole Merger,” Physical Review Letters, vol. 116, no. 6, Article ID 
061102, 2016. 
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Appendix 5 – Abstract of CHS symposium 2018 poster presentation  
 
Chronic hyperglycaemia as observed in Diabetes Mellitus (DM) has been shown to 
increase the probability of the non-enzymatic glycosylation of red blood cell membrane 
proteins resulting in the non-specific aggregation of protein molecules and alters the 
protein-protein and protein-lipid interaction leading to the modification and damage of 
the erythrocyte membrane (1). The modifications increase erythrocyte aggregation, 
decreased mobility of the red blood cells and increased blood viscosity which 
consequently elevates arterial pressure, this way inducing cardiac myopathy (2). 
However, the administration of insulin and other conventional drugs have been 
associated with the increased rate of agglutination of erythrocyte, increasing the 
viscosity of blood and consequently increases arterial pressure and disruption of 
erythrocyte function, which augments cardiac myopathy particularly in high 
cardiovascular risk diabetic patients (3). There is therefore a need for economical, 
alternative treatment such as medicinal plants for DM patients who are at risk of 
developing cardiovascular complications. Traditionally various plants have been shown 
to alleviate diabetes associated complications. Of interest to our study is Momordica 
balsamina. (MB) commonly known as “Intshungu” is a plant widespread in provinces 
of Southern Africa (4). In our laboratory, we have recently shown anti-
hyperglycaemicic and reno-protective effects of MB. However, the haemantic effects 
of this plant are not yet known (5, 6). 
 
 
